[{"role": "system", "content": "I am an assistant that extracts information about datasets from webpages. I always output a valid JSON array of objects. Each object will contain the following keys: 'dataset_id' and 'repository_reference', as follows: \n[\n  (\"dataset_id\": \"ABC1234\", \"repository_reference\": \"proteomexchange\")\n].\n\nImportant: The output must be a plain JSON array, not nested in any additional structure (e.g., no wrapping key like 'datasets')."}, {"role": "user", "content": "I have a webpage in HTML format (<html class=\"\" lang=\"en\"> <head> <link href=\"/static/assets/style-b3a36f11.css\" rel=\"stylesheet\"/> <link href=\"/static/assets/style-ef962842.css\" rel=\"stylesheet\"/> <link href=\"/static/assets/style-3ade8b5c.css\" rel=\"stylesheet\"/> <link href=\"/static/img/favicons/apple-touch-icon.png\" rel=\"apple-touch-icon\" sizes=\"180x180\"/> <link href=\"/static/img/favicons/favicon-48x48.png\" rel=\"icon\" sizes=\"48x48\" type=\"image/png\"/> <link href=\"/static/img/favicons/favicon-32x32.png\" rel=\"icon\" sizes=\"32x32\" type=\"image/png\"/> <link href=\"/static/img/favicons/favicon-16x16.png\" rel=\"icon\" sizes=\"16x16\" type=\"image/png\"/> <link href=\"/static/img/favicons/site.webmanifest\" rel=\"manifest\"/> <link color=\"#0071bc\" href=\"/static/img/favicons/safari-pinned-tab.svg\" rel=\"mask-icon\"/> <title> Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer - PMC </title> <link href=\"https://www.google-analytics.com\" rel=\"preconnect\"/> <link href=\"https://cdn.ncbi.nlm.nih.gov\" rel=\"preconnect\"/> <link href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8628860/\" rel=\"canonical\"/> </head> <body> <a class=\"usa-skipnav\" href=\"#main-content\"> Skip to main content </a> <section aria-label=\"Official website of the United States government\" class=\"usa-banner\"> <div class=\"usa-accordion\"> <header class=\"usa-banner__header\"> <div class=\"usa-banner__inner\"> <div class=\"grid-col-auto\"> <img alt=\"\" aria-hidden=\"true\" class=\"usa-banner__header-flag\" src=\"/static/img/us_flag.svg\"/> </div> <div aria-hidden=\"true\" class=\"grid-col-fill tablet:grid-col-auto\"> <p class=\"usa-banner__header-text\"> An official website of the United States government </p> <span class=\"usa-banner__header-action\"> Here's how you know </span> </div> <button aria-controls=\"gov-banner-default\" aria-expanded=\"false\" class=\"usa-accordion__button usa-banner__button\" type=\"button\"> <span class=\"usa-banner__button-text\"> Here's how you know </span> </button> </div> </header> <div class=\"usa-banner__content usa-accordion__content\" hidden=\"\" id=\"gov-banner-default\"> <div class=\"grid-row grid-gap-lg\"> <div class=\"usa-banner__guidance tablet:grid-col-6\"> <img alt=\"\" aria-hidden=\"true\" class=\"usa-banner__icon usa-media-block__img\" src=\"/static/img/icon-dot-gov.svg\"/> <div class=\"usa-media-block__body\"> <p> <strong> Official websites use .gov </strong> <br/> A <strong> .gov </strong> website belongs to an official government organization in the United States. </p> </div> </div> <div class=\"usa-banner__guidance tablet:grid-col-6\"> <img alt=\"\" aria-hidden=\"true\" class=\"usa-banner__icon usa-media-block__img\" src=\"/static/img/icon-https.svg\"/> <div class=\"usa-media-block__body\"> <p> <strong> Secure .gov websites use HTTPS </strong> <br/> A <strong> lock </strong> ( <span class=\"icon-lock\"> <svg aria-labelledby=\"banner-lock-description\" class=\"usa-banner__lock-image\" focusable=\"false\" height=\"64\" role=\"graphics-symbol\" viewbox=\"0 0 52 64\" width=\"52\" xmlns=\"http://www.w3.org/2000/svg\"> <title id=\"banner-lock-title\"> Lock </title> <desc id=\"banner-lock-description\"> Locked padlock icon </desc> <path d=\"M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z\" fill=\"#000000\" fill-rule=\"evenodd\"> </path> </svg> </span> ) or <strong> https:// </strong> means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. </p> </div> </div> </div> </div> </div> </section> <div class=\"usa-overlay\"> </div> <header class=\"usa-header usa-header--extended usa-header--wide\"> <div class=\"ncbi-header\"> <div class=\"ncbi-header__container\"> <a class=\"ncbi-header__logo-container\" href=\"https://www.ncbi.nlm.nih.gov/\"> <img alt=\" NCBI home page \" class=\"ncbi-header__logo-image\" src=\"/static/img/ncbi-logos/nih-nlm-ncbi--white.svg\"/> </a> <button aria-label=\"Show menu\" class=\"usa-menu-btn ncbi-header__hamburger-button\" type=\"button\"> <svg aria-hidden=\"true\" class=\"ncbi-hamburger-icon\" fill=\"none\" focusable=\"false\" height=\"21\" viewbox=\"0 0 31 21\" width=\"31\" xmlns=\"http://www.w3.org/2000/svg\"> <path clip-rule=\"evenodd\" d=\"M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z\" fill=\"#F1F1F1\" fill-rule=\"evenodd\"> </path> </svg> </button> <div class=\"ncbi-header__desktop-buttons\"> <button aria-controls=\"search-field-desktop-navigation\" aria-expanded=\"false\" aria-label=\"Show search overlay\" class=\"usa-button usa-button--unstyled ncbi-header__desktop-button\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon\" role=\"graphics-symbol\"> <use xlink:href=\"/static/img/sprite.svg#search\"> </use> </svg> Search </button> <div class=\"ncbi-header__login-dropdown\"> <button aria-controls=\"login-dropdown-menu\" aria-expanded=\"false\" aria-label=\"Show login menu\" class=\"usa-button usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon\" role=\"graphics-symbol\"> <use xlink:href=\"/static/img/sprite.svg#person\"> </use> </svg> <span> Log in </span> <svg aria-hidden=\"true\" class=\"usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden\" role=\"graphics-symbol\"> <use xlink:href=\"/static/img/sprite.svg#expand_less\"> </use> </svg> <svg aria-hidden=\"true\" class=\"usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden\" role=\"graphics-symbol\"> <use xlink:href=\"/static/img/sprite.svg#expand_more\"> </use> </svg> </button> <ul class=\"usa-nav__submenu ncbi-header__login-dropdown-menu\" hidden=\"\" id=\"login-dropdown-menu\"> <li class=\"usa-nav__submenu-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/myncbi/\"> Dashboard </a> </li> <li class=\"usa-nav__submenu-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/\"> Publications </a> </li> <li class=\"usa-nav__submenu-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/account/settings/\"> Account settings </a> </li> <li class=\"usa-nav__submenu-item\"> <button class=\"usa-button usa-button--outline ncbi-header__login-dropdown-logout-button\" type=\"button\"> Log out </button> </li> </ul> </div> </div> </div> </div> <div class=\"ncbi-search-panel ncbi--show-only-at-desktop\" hidden=\"\"> <div class=\"ncbi-search-panel__container\"> <form action=\"https://www.ncbi.nlm.nih.gov/search/all/\" aria-describedby=\"search-field-desktop-navigation-help-text\" autocomplete=\"off\" class=\"usa-search usa-search--big ncbi-search-panel__form\" method=\"GET\" role=\"search\"> <label class=\"usa-sr-only\" for=\"search-field-desktop-navigation\"> Search\u2026 </label> <input class=\"usa-input\" id=\"search-field-desktop-navigation\" name=\"term\" placeholder=\"Search NCBI\" type=\"search\" value=\"\"/> <button class=\"usa-button\" type=\"submit\"> <span class=\"usa-search__submit-text\"> Search NCBI </span> </button> </form> </div> </div> <nav aria-label=\"Primary navigation\" class=\"usa-nav\"> <p class=\"usa-sr-only\" id=\"primary-navigation-sr-only-title\"> Primary site navigation </p> <button aria-label=\"Close navigation menu\" class=\"usa-nav__close ncbi-nav__close-button\" type=\"button\"> <img alt=\"Close\" src=\"/static/img/usa-icons/close.svg\"/> </button> <form class=\"usa-search usa-search--small ncbi--hide-at-desktop margin-top-6\" role=\"search\"> <label class=\"usa-sr-only\" for=\"search-field\"> Search </label> <input class=\"usa-input\" id=\"search-field-mobile-navigation\" name=\"search\" placeholder=\"Search NCBI\" type=\"search\"/> <button class=\"usa-button\" type=\"submit\"> <img alt=\"Search\" class=\"usa-search__submit-icon\" src=\"data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg==\"/> </button> </form> <div class=\"ncbi-nav__mobile-login-menu ncbi--hide-at-desktop\" hidden=\"\"> <p class=\"ncbi-nav__mobile-login-menu-status\"> Logged in as: <strong class=\"ncbi-nav__mobile-login-menu-email\"> </strong> </p> <ul class=\"usa-nav__primary usa-accordion\"> <li class=\"usa-nav__primary-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/myncbi/\"> Dashboard </a> </li> <li class=\"usa-nav__primary-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/\"> Publications </a> </li> <li class=\"usa-nav__primary-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/account/settings/\"> Account settings </a> </li> </ul> </div> <button class=\"usa-button ncbi-nav__mobile-login-button ncbi--hide-at-desktop\" type=\"button\"> Log in </button> </nav> </header> <section aria-label=\"PMC Header with search box\" class=\"pmc-header pmc-header--basic\"> <div class=\"pmc-nav-container\"> <div class=\"pmc-header__bar\"> <div class=\"pmc-header__logo\"> <a aria-label=\"PMC Home\" href=\"/\" title=\"Home\"> </a> </div> <button aria-label=\"Open search\" class=\"usa-button usa-button--unstyled pmc-header__search__button\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4 pmc-icon__open\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#search\"> </use> </svg> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4 pmc-icon__close\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#close\"> </use> </svg> </button> </div> <div class=\"pmc-header__search\"> <form autocomplete=\"off\" class=\"usa-search usa-search--extra usa-search--article-right-column pmc-header__search__form\" role=\"search\"> <label class=\"usa-sr-only\" for=\"pmc-search\"> Search PMC Full-Text Archive </label> <span class=\"autoComplete_wrapper flex-1\"> <input aria-autocomplete=\"both\" aria-controls=\"autoComplete_list_1\" aria-expanded=\"false\" aria-haspopup=\"true\" aria-owns=\"autoComplete_list_1\" class=\"usa-input width-full maxw-none\" id=\"pmc-search\" name=\"term\" placeholder=\"Search PMC Full-Text Archive\" required=\"required\" role=\"combobox\" type=\"search\"/> <ul aria-label=\"Suggestions\" hidden=\"\" id=\"autoComplete_list_1\" role=\"listbox\"> </ul> </span> <button class=\"usa-button\" formaction=\"https://www.ncbi.nlm.nih.gov/pmc/\" type=\"submit\"> <span class=\"usa-search__submit-text\"> Search in PMC </span> <img alt=\"Search\" class=\"usa-search__submit-icon\" src=\"/static/img/usa-icons-bg/search--white.svg\"/> </button> </form> <ul class=\"pmc-header__search__menu\"> <li> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/pmc/advanced/\"> Advanced Search </a> </li> <li> <a class=\"usa-link\" href=\"/journals/\"> Journal List </a> </li> <li> <a class=\"usa-link\" href=\"/about/userguide/\"> User Guide </a> </li> </ul> </div> </div> </section> <div class=\"usa-section padding-top-0 desktop:padding-top-6 pmc-article-section\"> <div aria-label=\"Actions bar\" class=\"grid-container pmc-actions-bar is-not-intersecting\" role=\"complementary\"> <div class=\"grid-row\"> <div class=\"grid-col-fill display-flex\"> <div class=\"display-flex\"> <ul class=\"usa-list usa-list--unstyled usa-list--horizontal\"> <li class=\"margin-right-2 mobile-lg:margin-right-4 display-flex mob\"> <button aria-label=\"Open resources\" class=\"usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#more_vert\"> </use> </svg> </button> </li> <li class=\"margin-right-2 mobile-lg:margin-right-4 display-flex mob\"> <span class=\"usa-tooltip\"> <a aria-label=\"View on publisher site\" class=\"usa-link display-flex usa-tooltip__trigger\" href=\"https://doi.org/10.1016/j.ccell.2021.09.008\" rel=\"noreferrer noopener\" role=\"button\" tabindex=\"0\" target=\"_blank\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#launch\"> </use> </svg> </a> <span aria-hidden=\"true\" class=\"usa-tooltip__body\" role=\"tooltip\"> View on publisher site </span> </span> </li> <li class=\"margin-right-2 mobile-lg:margin-right-4 display-flex\"> <span class=\"usa-tooltip\"> <a aria-label=\"Download PDF\" class=\"usa-link display-flex usa-tooltip__trigger\" href=\"pdf/nihms-1754019.pdf\" role=\"button\" tabindex=\"0\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#file_download\"> </use> </svg> </a> <span aria-hidden=\"true\" class=\"usa-tooltip__body\" role=\"tooltip\"> Download PDF </span> </span> </li> <li class=\"margin-right-2 mobile-lg:margin-right-4 display-flex\"> <span class=\"usa-tooltip\"> <button aria-label=\"Save article in MyNCBI collections.\" class=\"usa-button usa-button--unstyled collections-dialog-trigger collections-button display-flex collections-button-empty usa-tooltip__trigger\" tabindex=\"0\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4 usa-icon--bookmark-full\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/action-bookmark-full.svg#icon\"> </use> </svg> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4 usa-icon--bookmark-empty\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/action-bookmark-empty.svg#icon\"> </use> </svg> </button> <span aria-hidden=\"true\" class=\"usa-tooltip__body\" role=\"tooltip\"> Add to Collections </span> </span> </li> <li class=\"margin-right-2 mobile-lg:margin-right-4 display-flex\"> <span class=\"usa-tooltip\"> <button aria-label=\"Open dialog with citation text in different styles\" class=\"usa-button usa-button--unstyled citation-dialog-trigger display-flex usa-tooltip__trigger\" role=\"button\" tabindex=\"0\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4 usa-icon--bookmark-empty\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#format_quote\"> </use> </svg> </button> <span aria-hidden=\"true\" class=\"usa-tooltip__body\" role=\"tooltip\"> Cite </span> </span> </li> <li class=\"pmc-permalink display-flex\"> <span class=\"usa-tooltip\"> <button aria-expanded=\"false\" aria-haspopup=\"true\" aria-label=\"Show article permalink\" class=\"usa-button usa-button--unstyled display-flex usa-tooltip__trigger\" tabindex=\"0\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#share\"> </use> </svg> </button> <span aria-hidden=\"true\" class=\"usa-tooltip__body\" role=\"tooltip\"> Permalink </span> </span> <div class=\"pmc-permalink__dropdown\" hidden=\"\"> <div class=\"pmc-permalink__dropdown__container\"> <h2 class=\"usa-modal__heading margin-top-0 margin-bottom-2\"> PERMALINK </h2> <div class=\"pmc-permalink__dropdown__content\"> <input aria-label=\"Article permalink\" class=\"usa-input\" type=\"text\" value=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8628860/\"/> <button aria-expanded=\"false\" class=\"usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0\" title=\"Copy article permalink\"> <svg aria-hidden=\"true\" class=\"usa-icon\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#content_copy\"> </use> </svg> <span class=\"margin-left-1\"> Copy </span> </button> </div> </div> </div> </li> </ul> </div> <button aria-label=\"Open article navigation\" class=\"usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#list\"> </use> </svg> </button> </div> </div> </div> <div class=\"grid-container desktop:padding-left-6\"> <div class=\"grid-row grid-gap\" id=\"article-container\"> <div class=\"grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content\"> <div class=\"grid-container padding-left-0 padding-right-0\"> <div class=\"grid-row desktop:margin-left-neg-6\"> <div class=\"grid-col-12\"> <div aria-label=\"Disclaimer note\" class=\"pmc-layout__disclaimer\" role=\"complementary\"> As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. <br/> Learn more: <a class=\"usa-link\" href=\"/about/disclaimer/\"> PMC Disclaimer </a> | <a class=\"usa-link\" href=\"/about/copyright/\"> PMC Copyright Notice </a> </div> </div> </div> <div class=\"grid-row pmc-wm desktop:margin-left-neg-6\"> <main class=\"usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0\" id=\"main-content\"> <section aria-label=\"Journal banner\" class=\"pmc-journal-banner text-center line-height-none\"> <img alt=\"NIHPA Author Manuscripts logo\" height=\"75\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-nihpa.png\" usemap=\"#pmc-banner-imagemap\" width=\"500\"/> <map name=\"pmc-banner-imagemap\"> <area alt=\"Link to NIHPA Author Manuscripts\" href=\"https://www.hhs.gov/open/public-access-guiding-principles/index.html\" rel=\"noopener noreferrer\" shape=\"default\" target=\"_blank\" title=\"Link to NIHPA Author Manuscripts\"/> </map> </section> <article lang=\"en\"> <section aria-label=\"Article citation and metadata\"> <section class=\"pmc-layout__citation font-secondary font-xs\"> <div> <div class=\"display-inline-block\"> <button aria-controls=\"journal_context_menu\" aria-expanded=\"false\" class=\"cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary\" type=\"button\"> Cancer Cell </button> </div> . Author manuscript; available in PMC: 2022 Nov 8. </div> <div> <em> Published in final edited form as: </em> Cancer Cell. 2021 Oct 14;39(11):1479\u20131496.e18. doi: <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.ccell.2021.09.008\" rel=\"noopener noreferrer\" target=\"_blank\"> 10.1016/j.ccell.2021.09.008 </a> </div> <nav hidden=\"hidden\" id=\"journal_context_menu\"> <ul class=\"menu-list font-family-ui\" role=\"menu\"> <li role=\"presentation\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/pmc/?term=%22Cancer%20Cell%22%5Bjour%5D\" role=\"menuitem\"> Search in PMC </a> </li> <li role=\"presentation\"> <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Cancer%20Cell%22%5Bjour%5D\" lang=\"en\" role=\"menuitem\"> Search in PubMed </a> </li> <li role=\"presentation\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Cancer%20Cell%22%5BTitle%20Abbreviation%5D\" role=\"menuitem\"> View in NLM Catalog </a> </li> <li role=\"presentation\"> <a class=\"usa-link\" href=\"?term=%22Cancer%20Cell%22%5Bjour%5D\" role=\"menuitem\"> Add to search </a> </li> </ul> </nav> </section> <section class=\"front-matter\"> <div class=\"ameta p font-secondary font-xs\"> <hgroup> <h1> Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer </h1> </hgroup> <div class=\"cg p\"> <a aria-describedby=\"id1\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Chan%20JM%22%5BAuthor%5D\"> <span class=\"name western\"> Joseph M Chan </span> </a> <div hidden=\"hidden\" id=\"id1\"> <h3> <span class=\"name western\"> Joseph M Chan </span> </h3> <div class=\"p\"> <sup> 1 </sup> Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. </div> <div class=\"p\"> <sup> 2 </sup> Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, 10016 USA. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Chan%20JM%22%5BAuthor%5D\"> <span class=\"name western\"> Joseph M Chan </span> </a> </div> </div> <sup> 1, </sup> <sup> 2, </sup> <sup> * </sup> , <a aria-describedby=\"id2\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Quintanal-Villalonga%20%C3%81%22%5BAuthor%5D\"> <span class=\"name western\"> \u00c1lvaro Quintanal-Villalonga </span> </a> <div hidden=\"hidden\" id=\"id2\"> <h3> <span class=\"name western\"> \u00c1lvaro Quintanal-Villalonga </span> </h3> <div class=\"p\"> <sup> 1 </sup> Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Quintanal-Villalonga%20%C3%81%22%5BAuthor%5D\"> <span class=\"name western\"> \u00c1lvaro Quintanal-Villalonga </span> </a> </div> </div> <sup> 1, </sup> <sup> * </sup> , <a aria-describedby=\"id3\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Gao%20VR%22%5BAuthor%5D\"> <span class=\"name western\"> Vianne Ran Gao </span> </a> <div hidden=\"hidden\" id=\"id3\"> <h3> <span class=\"name western\"> Vianne Ran Gao </span> </h3> <div class=\"p\"> <sup> 2 </sup> Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, 10016 USA. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Gao%20VR%22%5BAuthor%5D\"> <span class=\"name western\"> Vianne Ran Gao </span> </a> </div> </div> <sup> 2, </sup> <sup> * </sup> , <a aria-describedby=\"id4\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Xie%20Y%22%5BAuthor%5D\"> <span class=\"name western\"> Yubin Xie </span> </a> <div hidden=\"hidden\" id=\"id4\"> <h3> <span class=\"name western\"> Yubin Xie </span> </h3> <div class=\"p\"> <sup> 2 </sup> Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, 10016 USA. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Xie%20Y%22%5BAuthor%5D\"> <span class=\"name western\"> Yubin Xie </span> </a> </div> </div> <sup> 2, </sup> <sup> * </sup> , <a aria-describedby=\"id5\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Allaj%20V%22%5BAuthor%5D\"> <span class=\"name western\"> Viola Allaj </span> </a> <div hidden=\"hidden\" id=\"id5\"> <h3> <span class=\"name western\"> Viola Allaj </span> </h3> <div class=\"p\"> <sup> 1 </sup> Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Allaj%20V%22%5BAuthor%5D\"> <span class=\"name western\"> Viola Allaj </span> </a> </div> </div> <sup> 1 </sup> , <a aria-describedby=\"id6\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Chaudhary%20O%22%5BAuthor%5D\"> <span class=\"name western\"> Ojasvi Chaudhary </span> </a> <div hidden=\"hidden\" id=\"id6\"> <h3> <span class=\"name western\"> Ojasvi Chaudhary </span> </h3> <div class=\"p\"> <sup> 2 </sup> Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, 10016 USA. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Chaudhary%20O%22%5BAuthor%5D\"> <span class=\"name western\"> Ojasvi Chaudhary </span> </a> </div> </div> <sup> 2 </sup> , <a aria-describedby=\"id7\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Masilionis%20I%22%5BAuthor%5D\"> <span class=\"name western\"> Ignas Masilionis </span> </a> <div hidden=\"hidden\" id=\"id7\"> <h3> <span class=\"name western\"> Ignas Masilionis </span> </h3> <div class=\"p\"> <sup> 2 </sup> Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, 10016 USA. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Masilionis%20I%22%5BAuthor%5D\"> <span class=\"name western\"> Ignas Masilionis </span> </a> </div> </div> <sup> 2 </sup> , <a aria-describedby=\"id8\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Egger%20J%22%5BAuthor%5D\"> <span class=\"name western\"> Jacklynn Egger </span> </a> <div hidden=\"hidden\" id=\"id8\"> <h3> <span class=\"name western\"> Jacklynn Egger </span> </h3> <div class=\"p\"> <sup> 1 </sup> Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Egger%20J%22%5BAuthor%5D\"> <span class=\"name western\"> Jacklynn Egger </span> </a> </div> </div> <sup> 1 </sup> , <a aria-describedby=\"id9\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Chow%20A%22%5BAuthor%5D\"> <span class=\"name western\"> Andrew Chow </span> </a> <div hidden=\"hidden\" id=\"id9\"> <h3> <span class=\"name western\"> Andrew Chow </span> </h3> <div class=\"p\"> <sup> 1 </sup> Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Chow%20A%22%5BAuthor%5D\"> <span class=\"name western\"> Andrew Chow </span> </a> </div> </div> <sup> 1 </sup> , <a aria-describedby=\"id10\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Walle%20T%22%5BAuthor%5D\"> <span class=\"name western\"> Thomas Walle </span> </a> <div hidden=\"hidden\" id=\"id10\"> <h3> <span class=\"name western\"> Thomas Walle </span> </h3> <div class=\"p\"> <sup> 3 </sup> German Cancer Research Center (DKFZ), Clinical Cooperation Unit Virotherapy; National Center for Tumor Diseases (NCT), Department of Medical Oncology; German Cancer Consortium (DKTK), Heidelberg, Germany </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Walle%20T%22%5BAuthor%5D\"> <span class=\"name western\"> Thomas Walle </span> </a> </div> </div> <sup> 3 </sup> , <a aria-describedby=\"id11\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Mattar%20M%22%5BAuthor%5D\"> <span class=\"name western\"> Marissa Mattar </span> </a> <div hidden=\"hidden\" id=\"id11\"> <h3> <span class=\"name western\"> Marissa Mattar </span> </h3> <div class=\"p\"> <sup> 4 </sup> Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York, NY, 10065 USA. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Mattar%20M%22%5BAuthor%5D\"> <span class=\"name western\"> Marissa Mattar </span> </a> </div> </div> <sup> 4 </sup> , <a aria-describedby=\"id12\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Yarlagadda%20DVK%22%5BAuthor%5D\"> <span class=\"name western\"> Dig VK Yarlagadda </span> </a> <div hidden=\"hidden\" id=\"id12\"> <h3> <span class=\"name western\"> Dig VK Yarlagadda </span> </h3> <div class=\"p\"> <sup> 2 </sup> Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, 10016 USA. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Yarlagadda%20DVK%22%5BAuthor%5D\"> <span class=\"name western\"> Dig VK Yarlagadda </span> </a> </div> </div> <sup> 2 </sup> , <a aria-describedby=\"id13\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20JL%22%5BAuthor%5D\"> <span class=\"name western\"> James L Wang </span> </a> <div hidden=\"hidden\" id=\"id13\"> <h3> <span class=\"name western\"> James L Wang </span> </h3> <div class=\"p\"> <sup> 5 </sup> Department of Computer Science, Columbia University. New York, NY 10027 USA. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20JL%22%5BAuthor%5D\"> <span class=\"name western\"> James L Wang </span> </a> </div> </div> <sup> 5 </sup> , <a aria-describedby=\"id14\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Uddin%20F%22%5BAuthor%5D\"> <span class=\"name western\"> Fathema Uddin </span> </a> <div hidden=\"hidden\" id=\"id14\"> <h3> <span class=\"name western\"> Fathema Uddin </span> </h3> <div class=\"p\"> <sup> 1 </sup> Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Uddin%20F%22%5BAuthor%5D\"> <span class=\"name western\"> Fathema Uddin </span> </a> </div> </div> <sup> 1 </sup> , <a aria-describedby=\"id15\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Offin%20M%22%5BAuthor%5D\"> <span class=\"name western\"> Michael Offin </span> </a> <div hidden=\"hidden\" id=\"id15\"> <h3> <span class=\"name western\"> Michael Offin </span> </h3> <div class=\"p\"> <sup> 1 </sup> Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Offin%20M%22%5BAuthor%5D\"> <span class=\"name western\"> Michael Offin </span> </a> </div> </div> <sup> 1 </sup> , <a aria-describedby=\"id16\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Ciampricotti%20M%22%5BAuthor%5D\"> <span class=\"name western\"> Metamia Ciampricotti </span> </a> <div hidden=\"hidden\" id=\"id16\"> <h3> <span class=\"name western\"> Metamia Ciampricotti </span> </h3> <div class=\"p\"> <sup> 1 </sup> Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Ciampricotti%20M%22%5BAuthor%5D\"> <span class=\"name western\"> Metamia Ciampricotti </span> </a> </div> </div> <sup> 1 </sup> , <a aria-describedby=\"id17\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Qeriqi%20B%22%5BAuthor%5D\"> <span class=\"name western\"> Besnik Qeriqi </span> </a> <div hidden=\"hidden\" id=\"id17\"> <h3> <span class=\"name western\"> Besnik Qeriqi </span> </h3> <div class=\"p\"> <sup> 4 </sup> Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York, NY, 10065 USA. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Qeriqi%20B%22%5BAuthor%5D\"> <span class=\"name western\"> Besnik Qeriqi </span> </a> </div> </div> <sup> 4 </sup> , <a aria-describedby=\"id18\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Bahr%20A%22%5BAuthor%5D\"> <span class=\"name western\"> Amber Bahr </span> </a> <div hidden=\"hidden\" id=\"id18\"> <h3> <span class=\"name western\"> Amber Bahr </span> </h3> <div class=\"p\"> <sup> 4 </sup> Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York, NY, 10065 USA. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Bahr%20A%22%5BAuthor%5D\"> <span class=\"name western\"> Amber Bahr </span> </a> </div> </div> <sup> 4 </sup> , <a aria-describedby=\"id19\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22de%20Stanchina%20E%22%5BAuthor%5D\"> <span class=\"name western\"> Elisa de Stanchina </span> </a> <div hidden=\"hidden\" id=\"id19\"> <h3> <span class=\"name western\"> Elisa de Stanchina </span> </h3> <div class=\"p\"> <sup> 4 </sup> Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York, NY, 10065 USA. </div> <div class=\"p\"> <sup> 6 </sup> Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York, NY 10065, USA </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22de%20Stanchina%20E%22%5BAuthor%5D\"> <span class=\"name western\"> Elisa de Stanchina </span> </a> </div> </div> <sup> 4, </sup> <sup> 6 </sup> , <a aria-describedby=\"id20\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Bhanot%20UK%22%5BAuthor%5D\"> <span class=\"name western\"> Umesh K Bhanot </span> </a> <div hidden=\"hidden\" id=\"id20\"> <h3> <span class=\"name western\"> Umesh K Bhanot </span> </h3> <div class=\"p\"> <sup> 7 </sup> Precision Pathology Center, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Bhanot%20UK%22%5BAuthor%5D\"> <span class=\"name western\"> Umesh K Bhanot </span> </a> </div> </div> <sup> 7 </sup> , <a aria-describedby=\"id21\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Lai%20WV%22%5BAuthor%5D\"> <span class=\"name western\"> W Victoria Lai </span> </a> <div hidden=\"hidden\" id=\"id21\"> <h3> <span class=\"name western\"> W Victoria Lai </span> </h3> <div class=\"p\"> <sup> 1 </sup> Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Lai%20WV%22%5BAuthor%5D\"> <span class=\"name western\"> W Victoria Lai </span> </a> </div> </div> <sup> 1 </sup> , <a aria-describedby=\"id22\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Bott%20MJ%22%5BAuthor%5D\"> <span class=\"name western\"> Matthew J Bott </span> </a> <div hidden=\"hidden\" id=\"id22\"> <h3> <span class=\"name western\"> Matthew J Bott </span> </h3> <div class=\"p\"> <sup> 8 </sup> Thoracic Service, Department of Surgery; Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10065 USA. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Bott%20MJ%22%5BAuthor%5D\"> <span class=\"name western\"> Matthew J Bott </span> </a> </div> </div> <sup> 8 </sup> , <a aria-describedby=\"id23\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Jones%20DR%22%5BAuthor%5D\"> <span class=\"name western\"> David R Jones </span> </a> <div hidden=\"hidden\" id=\"id23\"> <h3> <span class=\"name western\"> David R Jones </span> </h3> <div class=\"p\"> <sup> 8 </sup> Thoracic Service, Department of Surgery; Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10065 USA. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Jones%20DR%22%5BAuthor%5D\"> <span class=\"name western\"> David R Jones </span> </a> </div> </div> <sup> 8 </sup> , <a aria-describedby=\"id24\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Ruiz%20A%22%5BAuthor%5D\"> <span class=\"name western\"> Arvin Ruiz </span> </a> <div hidden=\"hidden\" id=\"id24\"> <h3> <span class=\"name western\"> Arvin Ruiz </span> </h3> <div class=\"p\"> <sup> 9 </sup> Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065 USA. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Ruiz%20A%22%5BAuthor%5D\"> <span class=\"name western\"> Arvin Ruiz </span> </a> </div> </div> <sup> 9 </sup> , <a aria-describedby=\"id25\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Baine%20MK%22%5BAuthor%5D\"> <span class=\"name western\"> Marina K Baine </span> </a> <div hidden=\"hidden\" id=\"id25\"> <h3> <span class=\"name western\"> Marina K Baine </span> </h3> <div class=\"p\"> <sup> 9 </sup> Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065 USA. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Baine%20MK%22%5BAuthor%5D\"> <span class=\"name western\"> Marina K Baine </span> </a> </div> </div> <sup> 9 </sup> , <a aria-describedby=\"id26\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20Y%22%5BAuthor%5D\"> <span class=\"name western\"> Yanyun Li </span> </a> <div hidden=\"hidden\" id=\"id26\"> <h3> <span class=\"name western\"> Yanyun Li </span> </h3> <div class=\"p\"> <sup> 9 </sup> Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065 USA. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20Y%22%5BAuthor%5D\"> <span class=\"name western\"> Yanyun Li </span> </a> </div> </div> <sup> 9 </sup> , <a aria-describedby=\"id27\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Rekhtman%20N%22%5BAuthor%5D\"> <span class=\"name western\"> Natasha Rekhtman </span> </a> <div hidden=\"hidden\" id=\"id27\"> <h3> <span class=\"name western\"> Natasha Rekhtman </span> </h3> <div class=\"p\"> <sup> 9 </sup> Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065 USA. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Rekhtman%20N%22%5BAuthor%5D\"> <span class=\"name western\"> Natasha Rekhtman </span> </a> </div> </div> <sup> 9 </sup> , <a aria-describedby=\"id28\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Poirier%20JT%22%5BAuthor%5D\"> <span class=\"name western\"> John T Poirier </span> </a> <div hidden=\"hidden\" id=\"id28\"> <h3> <span class=\"name western\"> John T Poirier </span> </h3> <div class=\"p\"> <sup> 10 </sup> Perlmutter Cancer Center, New York University Langone Health, New York, NY 10065 USA. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Poirier%20JT%22%5BAuthor%5D\"> <span class=\"name western\"> John T Poirier </span> </a> </div> </div> <sup> 10 </sup> , <a aria-describedby=\"id29\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Nawy%20T%22%5BAuthor%5D\"> <span class=\"name western\"> Tal Nawy </span> </a> <div hidden=\"hidden\" id=\"id29\"> <h3> <span class=\"name western\"> Tal Nawy </span> </h3> <div class=\"p\"> <sup> 2 </sup> Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, 10016 USA. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Nawy%20T%22%5BAuthor%5D\"> <span class=\"name western\"> Tal Nawy </span> </a> </div> </div> <sup> 2 </sup> , <a aria-describedby=\"id30\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Sen%20T%22%5BAuthor%5D\"> <span class=\"name western\"> Triparna Sen </span> </a> <div hidden=\"hidden\" id=\"id30\"> <h3> <span class=\"name western\"> Triparna Sen </span> </h3> <div class=\"p\"> <sup> 1 </sup> Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. </div> <div class=\"p\"> <sup> 13 </sup> Weill Cornell Medical College, New York, NY 10065 USA. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Sen%20T%22%5BAuthor%5D\"> <span class=\"name western\"> Triparna Sen </span> </a> </div> </div> <sup> 1, </sup> <sup> 13 </sup> , <a aria-describedby=\"id31\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Mazutis%20L%22%5BAuthor%5D\"> <span class=\"name western\"> Linas Mazutis </span> </a> <div hidden=\"hidden\" id=\"id31\"> <h3> <span class=\"name western\"> Linas Mazutis </span> </h3> <div class=\"p\"> <sup> 11 </sup> Institute of Biotechnology, Vilnius University, Vilnius, Lithuania </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Mazutis%20L%22%5BAuthor%5D\"> <span class=\"name western\"> Linas Mazutis </span> </a> </div> </div> <sup> 11 </sup> , <a aria-describedby=\"id32\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Hollmann%20T%22%5BAuthor%5D\"> <span class=\"name western\"> Travis Hollmann </span> </a> <div hidden=\"hidden\" id=\"id32\"> <h3> <span class=\"name western\"> Travis Hollmann </span> </h3> <div class=\"p\"> <sup> 9 </sup> Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065 USA. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Hollmann%20T%22%5BAuthor%5D\"> <span class=\"name western\"> Travis Hollmann </span> </a> </div> </div> <sup> 9 </sup> , <a aria-describedby=\"id33\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Pe%E2%80%99er%20D%22%5BAuthor%5D\"> <span class=\"name western\"> Dana Pe\u2019er </span> </a> <div hidden=\"hidden\" id=\"id33\"> <h3> <span class=\"name western\"> Dana Pe\u2019er </span> </h3> <div class=\"p\"> <sup> 2 </sup> Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, 10016 USA. </div> <div class=\"p\"> <sup> 12 </sup> Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Pe%E2%80%99er%20D%22%5BAuthor%5D\"> <span class=\"name western\"> Dana Pe\u2019er </span> </a> </div> </div> <sup> 2, </sup> <sup> 12, </sup> <sup> # </sup> , <a aria-describedby=\"id34\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Rudin%20CM%22%5BAuthor%5D\"> <span class=\"name western\"> Charles M Rudin </span> </a> <div hidden=\"hidden\" id=\"id34\"> <h3> <span class=\"name western\"> Charles M Rudin </span> </h3> <div class=\"p\"> <sup> 1 </sup> Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. </div> <div class=\"p\"> <sup> 6 </sup> Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York, NY 10065, USA </div> <div class=\"p\"> <sup> 13 </sup> Weill Cornell Medical College, New York, NY 10065 USA. </div> <div class=\"p\"> <sup> 14 </sup> Lead contact </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Rudin%20CM%22%5BAuthor%5D\"> <span class=\"name western\"> Charles M Rudin </span> </a> </div> </div> <sup> 1, </sup> <sup> 6, </sup> <sup> 13, </sup> <sup> 14, </sup> <sup> # </sup> </div> <ul class=\"d-buttons inline-list\"> <li> <button aria-controls=\"aip_a\" aria-expanded=\"false\" class=\"d-button\"> Author information </button> </li> <li> <button aria-controls=\"anp_a\" aria-expanded=\"false\" class=\"d-button\"> Article notes </button> </li> <li> <button aria-controls=\"clp_a\" aria-expanded=\"false\" class=\"d-button\"> Copyright and License information </button> </li> </ul> <div class=\"d-panels font-secondary-light\"> <div class=\"d-panel p\" id=\"aip_a\"> <div class=\"p\" id=\"A1\"> <sup> 1 </sup> Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. </div> <div id=\"A2\"> <sup> 2 </sup> Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, 10016 USA. </div> <div id=\"A3\"> <sup> 3 </sup> German Cancer Research Center (DKFZ), Clinical Cooperation Unit Virotherapy; National Center for Tumor Diseases (NCT), Department of Medical Oncology; German Cancer Consortium (DKTK), Heidelberg, Germany </div> <div id=\"A4\"> <sup> 4 </sup> Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York, NY, 10065 USA. </div> <div id=\"A5\"> <sup> 5 </sup> Department of Computer Science, Columbia University. New York, NY 10027 USA. </div> <div id=\"A6\"> <sup> 6 </sup> Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York, NY 10065, USA </div> <div id=\"A7\"> <sup> 7 </sup> Precision Pathology Center, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. </div> <div id=\"A8\"> <sup> 8 </sup> Thoracic Service, Department of Surgery; Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10065 USA. </div> <div id=\"A9\"> <sup> 9 </sup> Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065 USA. </div> <div id=\"A10\"> <sup> 10 </sup> Perlmutter Cancer Center, New York University Langone Health, New York, NY 10065 USA. </div> <div id=\"A11\"> <sup> 11 </sup> Institute of Biotechnology, Vilnius University, Vilnius, Lithuania </div> <div id=\"A12\"> <sup> 12 </sup> Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. </div> <div id=\"A13\"> <sup> 13 </sup> Weill Cornell Medical College, New York, NY 10065 USA. </div> <div id=\"A14\"> <sup> 14 </sup> Lead contact </div> <div class=\"author-notes p\"> <div class=\"fn\" id=\"FN1\"> <sup> * </sup> <p class=\"display-inline\" id=\"P1\"> These authors contributed equally </p> </div> <div class=\"fn\" id=\"FN2\"> <p id=\"P2\"> AUTHOR CONTRIBUTIONS </p> <p id=\"P3\"> Conceptualization, J.M.C, A.Q.V., D.P. and C.M.R.; Methodology, J.M.C, A.Q.V., V.R.G., Y.X., D.P. and C.M.R.; Investigation, A.Q.V., V.A., O. C., I.M., J.E., F.U., B.Q., A.B., U.K.B., A.R., M.B. and N.R.; Formal Analysis: J.M.C, A.Q.V., V.R.G., Y.X., D.V.K.Y, J.L.W.; Data Curation: J.M.C, A.Q.V., T.N., J.E.; Writing \u2013 Original Draft, J.M.C, A.Q.V., V.R.G., Y.X., A.C., T.W., D.P. and C.M.R.; Writing \u2013 Review &amp; Editing, J.M.C, A.Q.V., V.R.G., Y.X., T.N., D.P. and C.M.R.; Funding Acquisition, D.P. and C.M.R.; Resources, M.M., W.V.L., M.J.B., D.R.J, M.O., M.C..; Supervision, T.N., T.S., L.M., T.H., D.P. and C.M.R. </p> </div> <div class=\"fn\" id=\"CR1\"> <sup> # </sup> <p class=\"display-inline\"> Correspondence: <span> peerster@gmail.com </span> (D.P.), <span> rudinc@mkcc.org </span> (C.M.R.) </p> </div> </div> </div> <div class=\"d-panel p\" id=\"anp_a\"> <div class=\"notes p\"> <section class=\"history\" id=\"historyarticle-meta1\"> <p> Issue date 2021 Nov 8. </p> </section> </div> </div> <div class=\"d-panel p\" id=\"clp_a\"> <div class=\"p\"> <a class=\"usa-link\" href=\"/about/copyright/\"> PMC Copyright notice </a> </div> </div> </div> <div> PMCID: PMC8628860 NIHMSID: NIHMS1754019 PMID: <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/34653364/\"> 34653364 </a> </div> <div aria-label=\"Related or updated information about this article\" class=\"ra xbox p\" role=\"complementary\"> <div> The publisher's version of this article is available at <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.ccell.2021.09.008\" rel=\"noopener noreferrer\" target=\"_blank\"> Cancer Cell </a> </div> </div> </div> </section> </section> <section aria-label=\"Article content\"> <section class=\"body main-article-body\"> <section class=\"abstract\" id=\"ABS1\"> <h2> <a class=\"usa-anchor\" id=\"ABS1-anchor\"> </a> SUMMARY </h2> <p id=\"P4\"> Small cell lung cancer (SCLC) is an aggressive malignancy that includes subtypes defined by differential expression of <em> ASCL1 </em> , <em> NEUROD1 </em> , and <em> POU2F3 </em> (SCLC-A, -N, and -P, respectively). To define the heterogeneity of tumors and their associated microenvironments across subtypes, we sequenced 155,098 transcriptomes from 21 human biospecimens, including 54,523 SCLC transcriptomes. We observe greater tumor diversity in SCLC than lung adenocarcinoma, driven by canonical, intermediate, and admixed subtypes. We discover a <em> PLCG2 </em> -high SCLC phenotype with stem-like, pro-metastatic features that recurs across subtypes and predicts worse overall survival. SCLC exhibits greater immune sequestration and less immune infiltration than lung adenocarcinoma, and SCLC-N shows less immune infiltrate and greater T-cell dysfunction than SCLC-A. We identify a profibrotic, immunosuppressive monocyte/macrophage population in SCLC tumors that is particularly associated with the recurrent, <em> PLCG2 </em> -high subpopulation. </p> <section class=\"kwd-group\" id=\"kwd-group1\"> <p> <strong> Keywords: </strong> SCLC, metastasis, scRNAseq, tumor atlas </p> </section> </section> <section class=\"abstract\" id=\"ABS2\"> <h2> <a class=\"usa-anchor\" id=\"ABS2-anchor\"> </a> eTOC Blurb </h2> <p id=\"P5\"> Chan et al. use single-cell transcriptome sequencing and imaging techniques to study the heterogeneity and tumor microenvironment of clinical small cell lung cancer specimens. This analysis identifies a <em> PLCG2 </em> -high expressing subpopulation linked to metastasis and poor prognosis, and an enrichment of a monocyte/macrophage population with a profibrotic, immunosuppressive phenotype. </p> </section> <section class=\"abstract\" id=\"ABS3\"> <h2> <a class=\"usa-anchor\" id=\"ABS3-anchor\"> </a> Graphical Abstract </h2> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <img alt=\"graphic file with name nihms-1754019-f0001.jpg\" class=\"graphic\" height=\"640\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e35b/8628860/ea1425432277/nihms-1754019-f0001.jpg\" width=\"640\"/> </p> </section> <section id=\"S1\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"S1-anchor\"> </a> INTRODUCTION </h2> <p id=\"P7\"> The prognosis for patients with small cell lung cancer (SCLC), the most aggressive lung cancer histology, remains exceptionally poor: most patients present with metastatic disease, and the recent addition of immune checkpoint blockade to first-line chemotherapy has only modestly improved median survival ( <a aria-describedby=\"R42\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R42\"> Horn et al., 2018a </a> ; <a aria-describedby=\"R79\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R79\"> Rudin et al., 2021 </a> ). The strong predilection for early metastasis and therapeutic resistance contribute to poor long-term outcomes, with 5-year survival of 15\u201330% for limited stage disease, and less than 1% for patients with extensive stage disease ( <a aria-describedby=\"R14\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R14\"> Byers and Rudin, 2015 </a> ; <a aria-describedby=\"R86\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R86\"> Siegel et al., 2020 </a> ). </p> <p id=\"P8\"> Although SCLC appears morphologically homogeneous, recent data from both murine models and human tumors suggest the existence of SCLC subtypes with distinct therapeutic vulnerabilities ( <a aria-describedby=\"R78\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R78\"> Rudin et al., 2019 </a> ). An emerging consensus has classified these subtypes based on differential expression of four transcription factors: <em> ASCL1 </em> , <em> NEUROD1 </em> , <em> POU2F3 </em> and <em> YAP1 </em> ( <a aria-describedby=\"R78\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R78\"> Rudin et al., 2019 </a> ). This classification has led to new questions, such as whether subtypes are associated with particular disease stages, metastatic potential or immune microenvironments, and whether there is plasticity between subtypes ( <a aria-describedby=\"R16\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R16\"> Chalishazar et al., 2019 </a> ; <a aria-describedby=\"R46\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R46\"> Ireland et al., 2020 </a> ; <a aria-describedby=\"R78\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R78\"> Rudin et al., 2019 </a> ). </p> <p id=\"P9\"> Single-cell RNA sequencing (scRNA-seq) offers a unique opportunity to address these questions by dissecting the intratumoral heterogeneity of SCLC and its tumor microenvironment (TME). Multiplexed ion beam imaging (MIBI) is a complementary technology that profiles multiple protein markers simultaneously at single-cell resolution in the spatial context of tissue. Efforts to apply these technologies to human SCLC tumors have been limited, as surgical resections of primary tumors are performed in under 5% of SCLC patients( <a aria-describedby=\"R97\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R97\"> Valli\u00e8res et al., 2009 </a> ), and biopsied samples are not typically preserved in a manner amenable to single-cell profiling. Since resection is only clinically indicated for very early stage <em> de novo </em> disease, these samples fail to capture the spectrum of disease progression. </p> <p id=\"P10\"> Here, we have constructed a single-cell atlas of SCLC patient tumors, with comparative lung adenocarcinoma (LUAD) and normal lung. Our analysis reveals high inter-patient transcriptomic diversity in SCLC and immune cells, largely driven by subtype-specific changes in cancer gene programs and immune dysfunction. In the midst of substantial heterogeneity, we identify a stem-like pro-metastatic tumor subpopulation marked by high <em> PLCG2 </em> expression that spans the full diversity of SCLC subtypes and predicts worse overall survival. Together, our analyses provide a deep characterization of the molecular features of SCLC, with clinical implications. </p> </section> <section id=\"S2\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"S2-anchor\"> </a> RESULTS </h2> <section id=\"S3\"> <h3 class=\"pmc_sec_title\"> Human SCLC tumors are more heterogeneous than LUAD </h3> <p id=\"P11\"> We profiled the transcriptomes of 155,098 cells from 21 fresh SCLC clinical samples ( <a class=\"usa-link\" href=\"#SD1\"> Figure S1A </a> , <a class=\"usa-link\" href=\"#SD2\"> Table S1 </a> ) obtained from 19 patients, as well as 24 LUAD and 4 tumor-adjacent normal lung samples as controls ( <a class=\"usa-link\" href=\"#F1\"> Figures 1A </a> and <a class=\"usa-link\" href=\"#SD1\"> S1B </a> ). The SCLC and LUAD cohorts include treated and untreated patients ( <a class=\"usa-link\" href=\"#F1\"> Figure 1B </a> ). Samples were obtained from primary tumors, regional lymph node metastases, and distant metastases (liver, adrenal gland, axilla, and pleural effusion) ( <a class=\"usa-link\" href=\"#F1\"> Figure 1C </a> ). </p> <figure class=\"fig xbox font-sm\" id=\"F1\"> <h4 class=\"obj_head\"> Figure 1: The single-cell transcriptional landscape of SCLC. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <img alt=\"Figure 1:\" class=\"graphic\" height=\"1890\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e35b/8628860/29c85a6c7eea/nihms-1754019-f0002.jpg\" width=\"2100\"/> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/F1/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p id=\"P183\"> LUAD and normal adjacent lung serve as reference tissues. </p> <p id=\"P184\"> (A) UMAP of iterative subsets of cells from the global level (left, n=155,098 cells) to the epithelial compartment (middle, n=64,301 cells) to SCLC cells (right, n=54,523 cells). Each dot represents a single cell colored by cell type. </p> <p id=\"P185\"> UMAP of SCLC cells annotated by (B) treatment history and (C) tissue site. </p> <p id=\"P186\"> Inter-patient heterogeneity within each cell type as measured by Shannon entropy for (D) all samples and (E) treatment-na\u00efve samples (Student\u2019s t-test, error bars: 95% confidence intervals; <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ). </p> <p id=\"P187\"> DC = dendritic cells, LN = lymph node, Chemo_1L = chemotherapy in first line, ChemoIO_1L = chemotherapy plus immunotherapy in first line, IO_2L = Immunotherapy in second line, later-line therapy = multiple lines of treatment. p-values: *&lt;0.05, **&lt;0.01, ***&lt;0.001. </p> <p id=\"P188\"> (F) UMAP of SCLC cells colored by subtype (red = SCLC-A, green = SCLC-N, blue = SCLC-P), based on maximum likelihood computed by our classifier. Sample RU1108 is labeled as a <em> TP53/RB1 </em> wild-type SCLC-A outlier ( <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ). </p> <p id=\"P189\"> (G) UMAP of imputed expression of <em> ASCL1 </em> , <em> NEUROD1 </em> , <em> POU2F3 </em> and <em> YAP1 </em> in the SCLC cohort using MAGIC <sup> 109 </sup> (k=30, t=3). Expression in units of log <sub> 2 </sub> (X+1) where X = normalized counts. </p> <p id=\"P190\"> (H) Ternary plot of SCLC subtype probability per cell, calculated by Markov absorption probabilities ( <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ). Cell color is assigned by the likelihood of SCLC-A (red), SCLC-N (green), and SCLC-P (blue). </p> <p id=\"P191\"> See also <a class=\"usa-link\" href=\"#SD1\"> Figures S1 </a> \u2013 <a class=\"usa-link\" href=\"#SD1\"> S2 </a> , and <a class=\"usa-link\" href=\"#SD2\"> Table S1 </a> . </p> </figcaption> </figure> <p id=\"P12\"> All scRNA-seq data were merged, normalized, batch-corrected, and clustered to identify coarse cell types, including epithelial, mesenchymal, lymphoid, and myeloid cells ( <a class=\"usa-link\" href=\"#F1\"> Figures 1A </a> and <a class=\"usa-link\" href=\"#SD1\"> S1B </a> \u2013 <a class=\"usa-link\" href=\"#SD1\"> C </a> ; <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ). Further clustering within the epithelial compartment identified cells comprising the respiratory epithelium (including alveolar epithelial types 1 and 2, ciliated, club, neuroendocrine and tuft cells) and hepatocytes derived from liver metastases. </p> <p id=\"P13\"> MSK-IMPACT <sup> \u2122 </sup> targeted sequencing ( <a aria-describedby=\"R18\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R18\"> Cheng et al., 2015 </a> ) of 14 SCLC samples demonstrated frequent mutation or loss of <em> RB1 </em> and <em> TP53 </em> , and recurrent mutations in <em> CREBBP </em> and <em> KMT2B </em> ( <a class=\"usa-link\" href=\"#SD1\"> Figure S1D </a> and <a class=\"usa-link\" href=\"#SD1\"> S1E </a> ). This information facilitated the identification of cancer cells that harbor transcripts bearing characteristic variants. We also inferred single-cell copy number variation (CNV) to support cancer cell identification ( <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ). We detected higher CNV levels in SCLC than LUAD ( <a class=\"usa-link\" href=\"#SD1\"> Figure S1F </a> ), consistent with higher tumor mutation burden in SCLC ( <a aria-describedby=\"R103\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R103\"> Yarchoan et al., 2019 </a> ). Based on studies investigating cell types of origin( <a aria-describedby=\"R30\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R30\"> Ferone et al., 2020 </a> ), we consider clusters of neuroendocrine and alveolar epithelial type 2-like cancer cells to represent SCLC and LUAD, respectively. </p> <p id=\"P14\"> Following cell type annotation, we characterized tumor heterogeneity within our atlas. Of 38 epithelial clusters (n = 64,301 cells), we found that LUAD and SCLC clustered separately as expected; 5 LUAD clusters contain 7,635 cells from 24 tumors and 25 SCLC clusters contain 55,815 cells from 21 tumors, consistent with the higher stromal content of LUAD. To quantify the inter-patient heterogeneity of SCLC, we calculated the Shannon entropy of patients for each cluster ( <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ). Low Shannon entropy signifies that the cluster phenotype is rarely shared across patients, i.e., inter-patient heterogeneity is high. Malignant SCLC cells showed significantly higher inter-patient heterogeneity (lower entropy) than LUAD cells ( <a class=\"usa-link\" href=\"#F1\"> Figure 1D </a> ), even when restricting analysis to treatment-na\u00efve samples ( <a class=\"usa-link\" href=\"#F1\"> Figure 1E </a> ). We observed low phenotypic diversity in stromal and immune cell populations, consistent with minimal batch effects across samples, and high diversity in neoplastic cells compared to stroma, consistent with prior studies ( <a aria-describedby=\"R4\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R4\"> Azizi et al., 2018 </a> ; <a aria-describedby=\"R74\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R74\"> Puram et al., 2017 </a> ). Our results suggest that, despite its homogeneous histological morphology, SCLC has a high degree of transcriptional tumor heterogeneity, exceeding that of LUAD and normal stroma. </p> </section> <section id=\"S4\"> <h3 class=\"pmc_sec_title\"> Tumor heterogeneity of canonical SCLC subtypes at single-cell resolution </h3> <p id=\"P15\"> Next, we considered the 54,523 SCLC cells in our dataset and characterized cell states within the canonical SCLC subtypes ( <a aria-describedby=\"R78\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R78\"> Rudin et al., 2019 </a> ) ( <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ). SCLC subtypes are typically classified by the expression of <em> ASCL1 </em> , <em> NEUROD1 </em> , <em> POU2F3 </em> and <em> YAP1 </em> , but a single-gene strategy is unreliable for scRNA-seq, given the prevalence of gene dropout. Recent studies from our group and others have also questioned the value of <em> YAP1 </em> alone as a subtype marker ( <a aria-describedby=\"R6\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R6\"> Baine et al., 2020 </a> ; <a aria-describedby=\"R70\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R70\"> Pearsall et al., 2020 </a> ). </p> <p id=\"P16\"> We therefore used a neighbor-graph-based approach, which harnesses multiple genes that define the full complexity of each subtype, to calculate the probability of a given SCLC subtype per cell ( <a aria-describedby=\"R55\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R55\"> Levine et al., 2015 </a> ) ( <a class=\"usa-link\" href=\"#F1\"> Figure 1F </a> ; <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ). We identified the most likely subtype of each cell ( <a class=\"usa-link\" href=\"#F1\"> Figure 1G </a> ) and used this to categorize the major subclone of each sample as SCLC-A (N = 14), SCLC-N (N = 6), or SCLC-P (N = 1). Our classification did not identify any SCLC-Y tumors, consistent with minimal expression of <em> YAP1 </em> in SCLC cells. This observation is supported by the relative expression of canonical transcription factors ( <a class=\"usa-link\" href=\"#F1\"> Figure 1H </a> ), corresponding MYC family members ( <a class=\"usa-link\" href=\"#SD1\"> Figure S1G </a> ), and matched immunohistochemistry (IHC) when available ( <a class=\"usa-link\" href=\"#SD1\"> Figure S1H </a> ). Unlike single-gene expression or IHC, our strategy can classify cases with high expression of both <em> ASCL1 </em> and <em> NEUROD1 </em> (such as Ru1231, classified as SCLC-N) and those with low expression of both (such as Ru1293, classified as SCLC-N due to expression of <em> NEUROD2 </em> and <em> NEUROD4 </em> ). We also identified intermediate cancer cells along the SCLC-A to SCLC-N spectrum, suggesting transitional or non-canonical phenotypes, as well as tumors of admixed subtype and a non-canonical SCLC phenotype with wild-type <em> TP53/RB1 </em> (see <a class=\"usa-link\" href=\"#SD1\"> Figures S2A </a> \u2013 <a class=\"usa-link\" href=\"#SD1\"> B </a> , <a class=\"usa-link\" href=\"#SD3\"> Table S2 </a> , and <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> for further details). </p> </section> <section id=\"S5\"> <h3 class=\"pmc_sec_title\"> SCLC-N exhibits a pro-metastatic neuronal and EMT phenotype </h3> <p id=\"P17\"> To better define the role of SCLC subtype in tumor progression, we assessed cell composition and gene expression differences across subtypes ( <a class=\"usa-link\" href=\"#SD1\"> Figure S2C </a> ). We focused on SCLC-A and -N, as our cohort only included a single SCLC-P case. Consistent with mouse models ( <a aria-describedby=\"R46\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R46\"> Ireland et al., 2020 </a> ; <a aria-describedby=\"R60\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R60\"> Mollaoglu et al., 2017 </a> ), SCLC-A is significantly overrepresented in primary tumors, whereas SCLC-N is enriched in nodal and distant metastases (Dirichlet regression, p&lt;3.4\u00d710 <sup> \u22128 </sup> ; <a class=\"usa-link\" href=\"#SD1\"> Figure S2D </a> ; <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ). We also observed greater interpatient diversity in SCLC-N tumors than in SCLC-A ( <a class=\"usa-link\" href=\"#F1\"> Figure 1D </a> ). These findings are consistent with preclinical models showing that SCLC-N can derive from SCLC-A through discrete evolutionary bottlenecks. </p> <p id=\"P18\"> We performed differential expression (DE) and pathway analysis to determine subtype-specific gene programs ( <a class=\"usa-link\" href=\"#F2\"> Figures 2A </a> and <a class=\"usa-link\" href=\"#SD1\"> S2E </a> ; <a class=\"usa-link\" href=\"#SD4\"> Tables S3 </a> \u2013 <a class=\"usa-link\" href=\"#SD10\"> 8 </a> ). We found that SCLC-A is enriched in expression of genes regulating cell cycle progression and DNA repair, as well as <em> EZH2 </em> target genes implicated in SCLC cell cycle regulation ( <a aria-describedby=\"R45\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R45\"> Hubaux et al., 2013 </a> ; <a aria-describedby=\"R72\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R72\"> Poirier et al., 2015 </a> ) ( <a class=\"usa-link\" href=\"#SD1\"> Figure S2E </a> ). In contrast, SCLC-N tumors exhibit a pro-metastatic pattern of gene expression including overexpressed markers of (1) epithelial-mesenchymal transition (EMT), ( <a aria-describedby=\"R23\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R23\"> Dongre and Weinberg, 2019a </a> ), (2) TGF-\u03b2( <a aria-describedby=\"R29\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R29\"> Farabaugh et al., 2012 </a> ), (3) BMP signaling ( <a aria-describedby=\"R19\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R19\"> Choi et al., 2019 </a> ; <a aria-describedby=\"R24\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R24\"> Dongre and Weinberg, 2019b </a> )( <a aria-describedby=\"R5\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R5\"> Bach et al., 2018 </a> ), (4) STAT ( <a aria-describedby=\"R24\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R24\"> Dongre and Weinberg, 2019b </a> ); and (5) TNF\u03b1-promoted NF\u03baB signaling ( <a aria-describedby=\"R47\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R47\"> Jiang et al., 2001 </a> ; <a aria-describedby=\"R101\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R101\"> Wu and Zhou, 2010 </a> ) ( <a class=\"usa-link\" href=\"#F2\"> Figures 2A </a> , <a class=\"usa-link\" href=\"#F2\"> 2B </a> and <a class=\"usa-link\" href=\"#SD1\"> S2E </a> ). </p> <figure class=\"fig xbox font-sm\" id=\"F2\"> <h4 class=\"obj_head\"> Figure 2: Gene programs and cell-cell interactions enriched in each SCLC subtype. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <img alt=\"Figure 2:\" class=\"graphic\" height=\"2100\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e35b/8628860/13fd5f984d0e/nihms-1754019-f0003.jpg\" width=\"1935\"/> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/F2/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p id=\"P192\"> (A) Dot plot showing selected DEGs between each SCLC subtype versus the rest, as well as between SCLC-A vs SCLC-N. DEGs are grouped by enriched gene pathways as assessed by GSEA (NES &gt; 1, FDR &lt; 0.1) ( <a class=\"usa-link\" href=\"#SD4\"> Tables S3 </a> \u2013 <a class=\"usa-link\" href=\"#SD9\"> 8 </a> ). Dot size = % cells expressing gene; dot color = mean expression scaled from 0 to 1. </p> <p id=\"P193\"> (B) Scaled expression of canonical markers or scaled average Z-score of select enriched pathways in SCLC-N (Y-axis), versus SCLC subtype probability (X-axis). Solid lines represent average gene/pathway trend ( <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ). </p> <p id=\"P194\"> (C) Enrichment of interactions between cancer cells within SCLC-A vs SCLC-N. Significant interactions are assessed using CellPhoneDB <sup> 102 </sup> . Enrichment of interactions within SCLC-A vs SCLC-N is plotted as significance (\u2212log <sub> 2 </sub> of Fisher\u2019s test) versus frequency. Dashed line corresponds to nominal p &lt; 0.05. </p> <p id=\"P195\"> See also <a class=\"usa-link\" href=\"#SD1\"> Figure S2 </a> and <a class=\"usa-link\" href=\"#SD2\"> Table S1 </a> . </p> </figcaption> </figure> <p id=\"P19\"> SCLC-N is also enriched in neuronal differentiation and neuropeptide signaling, including ephrins and semaphorins, gene families involved in axonogenic signaling ( <a aria-describedby=\"R71\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R71\"> Pitulescu and Adams, 2010 </a> ; <a aria-describedby=\"R104\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R104\"> Yoshida, 2012 </a> ) ( <a class=\"usa-link\" href=\"#F2\"> Figures 2A </a> , <a class=\"usa-link\" href=\"#F2\"> 2B </a> and <a class=\"usa-link\" href=\"#SD4\"> Table S3 </a> ). Prior studies have shown that the axonogenesis program coordinates neuronal migration ( <a aria-describedby=\"R105\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R105\"> Zhang et al., 2019a </a> ) and is implicated in SCLC metastasis ( <a aria-describedby=\"R102\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R102\"> Yang et al., 2019 </a> ), and ephrin and semaphorin pathway components are NEUROD1 targets ( <a aria-describedby=\"R12\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R12\"> Borromeo et al., 2016 </a> ) or regulators of the NEUROD1 <sup> high </sup> phenotype ( <a aria-describedby=\"R100\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R100\"> Wooten et al., 2019 </a> ) (see <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> for an in-depth characterization of enriched pathways in SCLC-A vs SCLC-N). </p> <p id=\"P20\"> We further assessed differentially expressed ligand-receptor pairs within subtypes ( <a class=\"usa-link\" href=\"#F2\"> Figure 2C </a> ; <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ), and observed marked enrichment in potential homotypic interactions between cancer cells in SCLC-N compared to SCLC-A. While one cannot be certain of any individual hypothesized ligand-receptor interaction in such analysis, the difference in the number of interactions between subtypes is striking and may reflect differential interactivity between subtypes. This enrichment is consistent with how SCLC-A cell lines typically grow as loose floating aggregates and SCLC-N lines grow as a tightly adherent monolayer in cell culture ( <a aria-describedby=\"R36\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R36\"> Gazdar et al., 1985 </a> ; <a aria-describedby=\"R78\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R78\"> Rudin et al., 2019 </a> ). </p> </section> <section id=\"S6\"> <h3 class=\"pmc_sec_title\"> A stem-like, pro-metastatic cell cluster recurs across patients and SCLC subtypes </h3> <p id=\"P21\"> The transcriptomic diversity of SCLC contrasts with the uniformly poor prognosis of patients. We analyzed phenotypes spanning multiple patients to determine whether any shared cell types may account for the universal aggressiveness of SCLC. Unsupervised clustering of the SCLC malignant cell compartment identified 25 clusters. Most clusters are specific to a single tumor, but cluster 22 is strikingly recurrent across samples (Mann-Whitney p &lt; 2.2\u00d710 <sup> \u221216 </sup> ) ( <a class=\"usa-link\" href=\"#F3\"> Figures 3A </a> \u2013 <a class=\"usa-link\" href=\"#F3\"> C </a> and <a class=\"usa-link\" href=\"#SD1\"> S3A </a> ; <a class=\"usa-link\" href=\"#SD2\"> Table S1 </a> ; <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ), spanning a range of treatment histories, tissue sites, and predominant subtypes ( <a class=\"usa-link\" href=\"#F3\"> Figure 3D </a> ). Cluster 22 comprises 166 cells, with 9 of 21 profiled tumors harboring at least 3% of the cluster. We confirmed that cells in the recurrent cluster have greater CNV burden than normal epithelial cells, consistent with a malignant phenotype ( <a class=\"usa-link\" href=\"#SD1\"> Figure S3B </a> ). </p> <figure class=\"fig xbox font-sm\" id=\"F3\"> <h4 class=\"obj_head\"> Figure 3: A subpopulation with metastatic, stem-like phenotype recurs broadly across SCLC tumors. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <img alt=\"Figure 3:\" class=\"graphic\" height=\"2100\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e35b/8628860/3c7df84563a7/nihms-1754019-f0004.jpg\" width=\"2081\"/> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/F3/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p id=\"P196\"> (A) Boxplot of subtype uncertainty of each SCLC cell stratfied by cluster (Y-axis; measured as entropy of subtype probabilities per cell within each cluster; error bars span 25 <sup> th </sup> to 75 <sup> th </sup> percentile), ordered by recurrence across patients (X-axis; measured as Shannon entropy of patients per cluster; <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ). </p> <p id=\"P197\"> (B) Stacked barplot of sample fraction per cluster, ordered by recurrence across patients, as in (A). </p> <p id=\"P198\"> (C) UMAP of SCLC cells with recurrent cluster 22 colored in black. </p> <p id=\"P199\"> (D) Proportion of samples comprising the recurrent cluster (9 of 21 profiled tumors harboring &gt;3% of the cluster). The number of cells per sample are indicated in parentheses for samples with the greatest representation of the recurrent cluster. Outer rings indicate the major intratumoral subtype (outer), tissue site (middle), and treatment history (inner). </p> <p id=\"P200\"> (E) Gene programs significantly enriched in cluster 22. Barplot of NES from GSEA for significantly enriched pathway (FDR &lt; 0.05 and NES &gt; 1; <a class=\"usa-link\" href=\"#SD10\"> Table S9 </a> ). </p> <p id=\"P201\"> (F) Genes ordered from most to least recurrently overexpressed along the X-axis, with recurrence score plotted on the Y-axis. The recurrence score is calculated as follows. Within each sample, DEGs were assessed between the recurrent cluster vs the rest of the tumor. The adjusted p-values for differential expression within each tumor are combined using Edgington\u2019s method. The recurrence score is the \u2212log of the combined p-value ( <a class=\"usa-link\" href=\"#SD12\"> Table S11 </a> ; <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ). </p> <p id=\"P202\"> (G) Violin plot with <em> PLCG2 </em> expression among individual cancer cells in our SCLC samples, grouped by tissue site (Bonferroni-adjusted Mann-Whitney test). Expression is plotted as log2(X+1) where X is the normalized count, imputed using MAGIC (k=30, t=3). </p> <p id=\"P203\"> See also <a class=\"usa-link\" href=\"#SD1\"> Figure S3 </a> and <a class=\"usa-link\" href=\"#SD2\"> Table S1 </a> . </p> </figcaption> </figure> <p id=\"P22\"> Cells in the recurrent cluster exhibit significantly higher uncertainty in subtype assignment than those in any other cluster (Mann-Whitney p &lt; 2.2\u00d710 <sup> \u221216 </sup> ), suggesting a dedifferentiated phenotype ( <a class=\"usa-link\" href=\"#F3\"> Figure 3A </a> ; <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ). These cells are enriched in genes and gene programs related to metastasis and neural stem cells ( <a class=\"usa-link\" href=\"#F3\"> Figures 3E </a> and <a class=\"usa-link\" href=\"#F3\"> 3F </a> ; <a class=\"usa-link\" href=\"#SD10\"> Table S9 </a> ). In microarray data from SCLC-A and SCLC-N cell lines in the Cancer Cell Line Encyclopedia (CCLE) database (N = 54), we confirmed that the gene signature for the recurrent cluster was significantly positively correlated with many of the same pathways associated with metastasis, chemotaxis, and stemness ( <a class=\"usa-link\" href=\"#SD1\"> Figure S3C </a> ; <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ). </p> <p id=\"P23\"> Within Cluster 22, <em> phospholipase C gamma 2 </em> ( <em> PLCG2 </em> ) was the top differentially upregulated gene ( <a class=\"usa-link\" href=\"#F3\"> Figures 3F </a> and <a class=\"usa-link\" href=\"#SD1\"> S3D </a> ; <a class=\"usa-link\" href=\"#SD11\"> Tables S10 </a> and <a class=\"usa-link\" href=\"#SD12\"> S11 </a> ). <em> PLCG2 </em> has been previously implicated in Alzheimer\u2019s disease ( <a aria-describedby=\"R15\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R15\"> Castillo et al., 2017 </a> ; <a aria-describedby=\"R54\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R54\"> van der Lee et al., 2019 </a> ) and its paralog <em> PLCG1 </em> promotes metastasis ( <a aria-describedby=\"R48\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R48\"> Kassis et al., 1999 </a> ; <a aria-describedby=\"R80\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R80\"> Sala et al., 2008 </a> ). We used knnDREMI ( <a aria-describedby=\"R22\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R22\"> Dijk et al., 2018 </a> ), which is well suited to handle data sparsity and rare cell populations, to explore the full gene program that covaries with <em> PLCG2 </em> ( <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ). We grouped results from knnDREMI into three gene modules corresponding to low (module 1), medium (module 2) and high <em> PLCG2 </em> expression (module 3) ( <a class=\"usa-link\" href=\"#SD1\"> Figure S3E </a> ; <a class=\"usa-link\" href=\"#SD13\"> Table S12 </a> ). Candidate genes in module 3 included <em> FGFR1 </em> (implicated in SCLC through frequent amplifications ( <a aria-describedby=\"R28\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R28\"> Elakad et al., 2020 </a> )), and <em> MTRNR2L8 </em> and <em> MTRNR2L12 </em> (humanin family genes shown to inhibit apoptosis ( <a aria-describedby=\"R63\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R63\"> Morris et al., 2020 </a> ), to be neuroprotective in Alzheimer\u2019s disease ( <a aria-describedby=\"R52\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R52\"> Kusakari et al., 2018 </a> ), and to promote tumor progression in triple-negative breast cancer ( <a aria-describedby=\"R62\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R62\"> Moreno Ayala et al., 2020 </a> )). Among the top 5% of pathways most correlated to module 3 were those related to stemness (including <em> OCT4 </em> and <em> SOX2 </em> targets), metastatic gene signatures, and pro-metastatic signaling pathways (including Wnt and BMP signaling) ( <a aria-describedby=\"R24\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R24\"> Dongre and Weinberg, 2019b </a> ) ( <a class=\"usa-link\" href=\"#SD1\"> Figures S3E </a> and <a class=\"usa-link\" href=\"#SD1\"> S3F </a> ; <a class=\"usa-link\" href=\"#SD14\"> Table S13 </a> ). </p> </section> <section id=\"S7\"> <h3 class=\"pmc_sec_title\"> <em> PLCG2 </em> expression is associated with increased stem-like and pro-metastatic potential </h3> <p id=\"P24\"> Among the multiple ovexpressed genes in the recurrent SCLC cluster ( <a class=\"usa-link\" href=\"#F3\"> Figure 3F </a> ), we began by investigating the role of <em> PLCG2 </em> as a potential driver of progression. Consistent with the suggested pro-metastatic phenotype of the recurrent cluster, <em> PLCG2 </em> is significantly upregulated in metastatic sites compared to lung, with highest levels in the liver, the most common site of SCLC metastasis ( <a class=\"usa-link\" href=\"#F3\"> Figure 3G </a> ). These observations prompted us to test <em> PLCG2 </em> function directly by overexpressing the gene in SCLC cell lines with relatively low <em> PLCG2 </em> expression (SHP-77, SCLC-A; H82 and H446, SCLC-N) and by knocking it out in <em> PLCG2 </em> -high SCLC cell lines (H526, SCLC-P; DMS114, SCLC-Y). Exogenous PLCG2 overexpression did not affect proliferation (data not shown) but did increase anchorage-independent growth ( <a class=\"usa-link\" href=\"#SD1\"> Figure S3G </a> ). Additionally, PLCG2 expression was associated with higher migration and invasion <em> in vitro </em> ( <a class=\"usa-link\" href=\"#F4\"> Figure 4A </a> ) and with higher metastatic potential <em> in vivo </em> following intracardiac injection ( <a class=\"usa-link\" href=\"#F4\"> Figures 4B </a> and <a class=\"usa-link\" href=\"#F4\"> 4C </a> ), consistent with the pro-metastatic expression profile of the recurrent cluster. Western blot analyses validated key phenotypes observed in the single-cell data including (1) increased \u03b2-catenin expression, suggesting higher Wnt signaling, which was confirmed in a Wnt reporter assay ( <a class=\"usa-link\" href=\"#SD1\"> Figure S3H </a> ); (2) increased SMAD1/5 phosphorylation, consistent with higher BMP signaling; (3) increased expression of EMT/metastatic markers and (4) higher levels of stemness-related markers ( <a class=\"usa-link\" href=\"#F4\"> Figure 4D </a> ). These results suggest that PLCG2 may be partially driving a stem-like, pro-metastatic phenotype in the recurrent cluster. </p> <figure class=\"fig xbox font-sm\" id=\"F4\"> <h4 class=\"obj_head\"> Figure 4: A role for the PLCG2+ recurrent cluster in metastasis and patient outcome associated with PLCG2 expression. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <img alt=\"Figure 4:\" class=\"graphic\" height=\"2100\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e35b/8628860/4c766117349a/nihms-1754019-f0005.jpg\" width=\"1614\"/> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/F4/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p id=\"P204\"> (A) Migration (top) and invasion (bottom) assays for <em> PLCG2 </em> -overexpressing cell lines (SHP-77, H446, and H82) and <em> PLCG2 </em> -CRISPR KO polyclonal (H526, DMS-114) cell lines, measured with a luminometric method in at least 3 independent experiments (3 technical replicates/experiment). Log2 fold change over control condition was calculated (two-tailed Student\u2019s t-test; error bars: standard deviation). </p> <p id=\"P205\"> (B) Luminescence imaging of mice at day 31 following intracardiac injection to assess metastatic capacity of <em> PLCG2 </em> -overexpressing SHP77 cells and <em> PLCG2 </em> -KO polyclonal H526 cells. </p> <p id=\"P206\"> (C) Barplot showing the percentage of mice with metastasis in <em> in vivo </em> intracardiac injections of <em> PLCG2 </em> -overexpressing SHP-77 and PLCG2-downregulated H526 cell lines in mice compared to control conditions (Fisher\u2019s exact test). </p> <p id=\"P207\"> (D) Western blots of markers associated with signaling pathways upregulated in cluster 22 (Wnt and BMP pathways), EMT/metastasis, and stemness in PLCG2-overexpressing and -KO polyclonal cell lines. </p> <p id=\"P208\"> (E) Color overlay of PLCG2 (red), NEUROD1 (cyan), and dsDNA (violet) channels in SCLC tumor MIBI 1 from field of view (FoV) 2 (800 \u00d7 800 \u03bcm), illustrating high fraction of PLCG2-positive cancer cells. Error bars: 95% confidence interval. </p> <p id=\"P209\"> (F) Same FoV as (E) now visualized based on segmented cancer cells using Mesmer ( <a aria-describedby=\"R39\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R39\"> Greenwald et al., 2021 </a> ), represented by dots colored by PLCG2 positivity. Error bars: 95% confidence interval. </p> <p id=\"P210\"> (G) Scatterplot of the percent of PLCG2-positive SCLC cells per sample using MIBI-TOF vs overall survival (months) in an independent TMA cohort, annotated by percent of PLCG2+ SCLC cells &gt;7% (cyan) and deceased patient (triangle). Spearman\u2019s correlation r and example patient MIBI 1 from <a class=\"usa-link\" href=\"#F4\"> Figures 4E </a> \u2013 <a class=\"usa-link\" href=\"#F4\"> F </a> are shown. </p> <p id=\"P211\"> (H) Kaplan-Meier analysis of OS in an independent cohort of SCLC patients ( <a class=\"usa-link\" href=\"#SD15\"> Table S14 </a> ) with high vs low <em> PLCG2 </em> positivity (&gt;7% vs \u22647% of SCLC cells with high PLCG2 staining intensity), as assessed by MIBI-TOF on a TMA. Note that the adjusted Cox proportional hazards model using the fraction of PLCG2-positive SCLC cells as a continuous rather than dichotomized covariate was also significantly predictive (p = 0.012, <a class=\"usa-link\" href=\"#S14\"> STAR methods </a> ). </p> <p id=\"P212\"> (I) Scatterplot of the percent of the recurrent SCLC cluster per sample using scRNA-seq (log10 scale) vs overall survival (months), annotated by percent of recurrent cluster &gt; 0.75% (cyan) and deceased patients (triangle). Spearman\u2019s correlation r is indicated. </p> <p id=\"P213\"> (J) Kaplan-Meier analysis of OS in patients with detectable PLCG2+ recurrent cluster cells by scRNA-seq (&gt;0.75% vs \u22640.75% of SCLC cells) ( <a class=\"usa-link\" href=\"#SD17\"> Table S16 </a> ). Note that the adjusted Cox proportional hazards model using the fraction of the recurrent cluster as a continuous rather than dichotomized covariate was also significantly predictive (p = 0.009, <a class=\"usa-link\" href=\"#S14\"> STAR methods </a> ). PLCG2 = PLCG2 overexpression, sgPLCG2 = CRISPR knockout. See also <a class=\"usa-link\" href=\"#SD1\"> Figure S1 </a> and <a class=\"usa-link\" href=\"#SD2\"> Tables S1 </a> , <a class=\"usa-link\" href=\"#SD15\"> S14 </a> , and <a class=\"usa-link\" href=\"#SD17\"> S16 </a> . </p> </figcaption> </figure> </section> <section id=\"S8\"> <h3 class=\"pmc_sec_title\"> <em> PLCG2 </em> and the recurrent cluster are associated with reduced overall survival in patients </h3> <p id=\"P25\"> To determine the clinical significance of <em> PLCG2 </em> expression, we performed MIBI imaging on a tissue microarray (TMA) representing an independent cohort of SCLC tumor specimens (N = 37; <a class=\"usa-link\" href=\"#SD15\"> Table S14 </a> ). We optimized cell-type-specific antibodies ( <a class=\"usa-link\" href=\"#SD16\"> Table S15 </a> ) in combination with kernel density estimation of cells ( <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ) to identify SCLC, immune, and stromal cell types ( <a class=\"usa-link\" href=\"#SD1\"> Figure S4A </a> ), which were consistent with IHC review of an adjacent TMA section by a pathologist (data not shown). Using a monoclonal PLCG2 antibody, we identified a subset of patient tumors with high fraction of cancer cells expressing PLCG2, as exemplified by patient MIBI 1 ( <a class=\"usa-link\" href=\"#F4\"> Figures 4E </a> \u2013 <a class=\"usa-link\" href=\"#F4\"> F </a> , <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ). Considering only tumors that were ever extensive-stage (either at initial diagnosis or upon relapse; N = 27 passing quality control, see <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ), we found that the presence of PLCG2-expressing cancer cells is negatively correlated with overall survival (Spearman\u2019s correlation r = \u22120.34; t-test p = 0.04; <a class=\"usa-link\" href=\"#F4\"> Figure 4G </a> ). Kaplan-Meier analysis revealed worse overall survival in patients with tumors exhibiting high PLCG2 expression (&gt;7% of SCLC cells with high PLCG2 intensity; p = 0.00062; <a class=\"usa-link\" href=\"#F4\"> Figure 4H </a> ). An adjusted Cox proportional hazards model confirmed decreased overall survival (p = 0.041) and showed furthermore that high PLCG2 positivity is a stronger predictor of worse outcome than treatment history, presence of metastatic disease, or SCLC subtype ( <a class=\"usa-link\" href=\"#SD1\"> Figure S4B </a> ). The same model, using the fraction of PLCG2-positive SCLC cells as a continuous rather than dichotomized covariate, was also significantly predictive (p = 0.012), indicating that the analysis does not depend on selecting a threshold for PLCG2-positive SCLC cells. </p> <p id=\"P26\"> <em> PLCG2 </em> overexpression is just one feature of the recurrent cluster phenotype. We also assessed whether the prevalence of this subpopulation has prognostic significance, and found that the fractional representation of recurrent cluster cells (log fraction out of all cancer cells in each tumor) is negatively correlated with overall survival (Spearman\u2019s correlation r = \u22120.65; asymptotic t-test = 0.009; <a class=\"usa-link\" href=\"#F4\"> Figure 4I </a> ). Patients for whom this subpopulation represents &gt;0.75% of total cancer cells had significantly decreased overall survival relative to others (p = 0.008; <a class=\"usa-link\" href=\"#F4\"> Figure 4J </a> ; <a class=\"usa-link\" href=\"#SD17\"> Table S16 </a> ). An adjusted Cox proportional hazards model confirmed worse overall survival and greater hazard ratio than <em> PLCG2 </em> positivity in the MIBI analysis (44.4 vs 5.47); <em> PLCG2 </em> positivity is a strong predictor, but less so than the full transcriptional phenotype of the recurrent cluster ( <a class=\"usa-link\" href=\"#SD1\"> Figure S4C </a> ). We repeated this analysis using recurrent cluster fraction as a continuous covariate and confirmed significantly worse survival without pre-selecting a threshold (p = 0.009). Taken together, these data support that a small stem-like, pro-metastatic subpopulation with high <em> PLCG2 </em> expression has a remarkably large prognostic impact across SCLC subtypes. </p> </section> <section id=\"S9\"> <h3 class=\"pmc_sec_title\"> Immune cells in the SCLC TME are fewer and more sequestered </h3> <p id=\"P27\"> SCLC is recognized as a particularly immune-cold cancer <sup> 46 </sup> , and the addition of immune checkpoint blockade to standard-of-care chemotherapy only modestly improves median survival ( <a aria-describedby=\"R43\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R43\"> Horn et al., 2018b </a> ; <a aria-describedby=\"R69\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R69\"> Paz-Ares et al., 2019 </a> ). However, recent findings suggest some subtype-dependent heterogeneity in immunogenicity ( <a aria-describedby=\"R10\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R10\"> Best et al., 2020a </a> ; <a aria-describedby=\"R25\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R25\"> Dora et al., 2020 </a> ; <a aria-describedby=\"R34\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R34\"> Gay et al., 2021a </a> ; <a aria-describedby=\"R65\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R65\"> Owonikoko et al., 2021 </a> ), including a non-NE inflamed SCLC subtype ( <a aria-describedby=\"R35\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R35\"> Gay et al., 2021b </a> ). Understanding the role of subtype in shaping the immune environment will be key to developing effective interventions. However, a comprehensive characterization of the SCLC immune compartment has not been feasible due to limited biospecimen availability and the poor accuracy of low-abundance cell type deconvolution from bulk RNA-seq data. </p> <p id=\"P28\"> We aimed to assess the influence of SCLC subtype on the immune TME. Our scRNA-seq dataset could not be used to assess total immune cell abundance, since we enriched for non-immune (CD45\u2212) cells by sorting ( <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ). Instead, we analyzed flow cytometry data from this cohort, as well as an independent SCLC cohort (N = 11, <a class=\"usa-link\" href=\"#SD18\"> Table S17 </a> ). Focusing on SCLC-A and SCLC-N, we confirmed fewer CD45+ cells than LUAD, and found further reduction specifically in SCLC-N and NEUROD1-positive tumors ( <a class=\"usa-link\" href=\"#SD1\"> Figures S4D </a> and <a class=\"usa-link\" href=\"#SD1\"> S4E </a> ), consistent with prior bulk RNA-seq data suggesting that NEUROD1-positive tumors express lower levels of immune-related genes ( <a aria-describedby=\"R11\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R11\"> Best et al., 2020b </a> ). </p> <p id=\"P29\"> We next sought to characterize the spatial architecture of the immune TME using MIBI on an independent cohort with available NEUROD1 staining (N = 33). Following a prior definition of immune-hot tumors as harboring &gt; 250 immune cells in an 800 \u00d7 800 \u03bcm field of view (FoV) ( <a aria-describedby=\"R49\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R49\"> Keren et al., 2018a </a> ), we found that the majority of SCLC tumors (20 out of 33) in this cohort were immune cold. Moreover, significantly more NEUROD1+ SCLC tumors are immune cold (univariate test - Fisher\u2019s exact p = 0.0066; <a class=\"usa-link\" href=\"#F5\"> Figures 5A </a> , <a class=\"usa-link\" href=\"#F5\"> 5B </a> and <a class=\"usa-link\" href=\"#SD1\"> S4F </a> ). To account for possible confounders, we modeled immune infiltration (hot vs. cold) as a logistic regression that incorporates clinical covariates including NEUROD1 positivity, histology (single vs. admixed with adenocarcinoma), treatment (treated vs. naive) and location (primary vs. metastatic). The regression model found that tumor location separates predictions of immune infiltration, with immune-cold tumors represented by all 5 metastases and 15 of 28 primaries. Upon adjusting for all clinical covariates, including tumor location, only NEUROD1 positivity is a significant predictor of immune-cold status (Student\u2019s t-test p = 0.037; <a class=\"usa-link\" href=\"#SD1\"> Figure S4G </a> ). </p> <figure class=\"fig xbox font-sm\" id=\"F5\"> <h4 class=\"obj_head\"> Figure 5: Analysis of therapy and subtype-specific changes in immune phenotype indicate suppressed T-cell activity in SCLC-N. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <img alt=\"Figure 5:\" class=\"graphic\" height=\"2100\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e35b/8628860/0a7ec9158020/nihms-1754019-f0006.jpg\" width=\"1626\"/> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/F5/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p id=\"P214\"> (A) Comparison of MIBI images depicting NEUROD1\u2212 SCLC tumor MIBI 27 from FoV 2 (left) and NEUROD1+ SCLC tumor MIBI 16 from FoV 1 (right) (each FoV 800 \u00d7 800 \u03bcm), illustrating differences in immune abundance and sequestration. Top: Color overlay of NEUROD1 (red), CD3 (green), CD14 (white), CD68 (orange), CD163 (yellow), and dsDNA (violet) channels. Bottom: FoV from the top panel now visualized with segmented cancer cells using Mesmer( <a aria-describedby=\"R39\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R39\"> Greenwald et al., 2021 </a> ), represented by dots colored by cell type (immune, tumor, and stroma). </p> <p id=\"P215\"> (B) Boxplot comparing the percent of immune out of total cells between NEUROD1\u2212 vs NEUROD1+ SCLC cells. The overlying swarmplot is colored by hot (red) vs cold (blue) where hot is defined as number of immune cells &gt; 250 in an 800 \u00d7 800 \u03bcm FoV (N=33, Fisher\u2019s exact test; error bars: 95% confidence intervals). </p> <p id=\"P216\"> (C) The probability distribution of the immune-tumor mixing score in SCLC vs TNBC, defined as the number of interactions between immune and cancer cells divided by the number of interactions between immune and non-cancer cells (N=47, Welch\u2019s t-test). </p> <p id=\"P217\"> (D) UMAPs of SCLC immune subsets. Tconv = conventional T-cell; Treg = regulatory T-cell; Teff = effector T-cell; Tmem = memory T-cell; Tgd = \u03b3\u03b4 T-cell; Mono/M\u03c6 = monocyte/macrophage; PMN = neutrophil; cDC = conventional dendritic cell; pDC = plasmacytoid dendritic cell. </p> <p id=\"P218\"> (E) Barplot comparing CD8+ Teff/Treg log ratio based on NMF cell loadings associated with T-cell phenotype in SCLC-A vs SCLC-N in our single-cell cohort (N=19), adjusted for treatment and tissue site (weighted t-test; error bars: 95% confidence interval). </p> <p id=\"P219\"> (F) Barplot comparing CD8+ T/Treg log ratio in NEUROD1\u2212 vs NEUROD1+ SCLC in an independent cohort with Vectra imaging (N=12; weighted t-test; error bars: 95% confidence interval). </p> <p id=\"P220\"> (G) Select Vectra imaging of NEUROD1\u2212 vs NEUROD1+ SCLC (2 samples each). Fluorescent markers include CD8 (cytotoxic T-cells), Foxp3 (Tregs), INSM1/CK7 (epithelial and cancer cells), and DAPI (DNA). CD8 (green) or Foxp3 (pink) positivity of segmented cells are shown. </p> <p id=\"P221\"> See also <a class=\"usa-link\" href=\"#SD1\"> Figures S4 </a> \u2013 <a class=\"usa-link\" href=\"#SD1\"> S5 </a> and <a class=\"usa-link\" href=\"#SD15\"> Tables S14 </a> , <a class=\"usa-link\" href=\"#SD18\"> S17 </a> , and <a class=\"usa-link\" href=\"#SD19\"> S18 </a> . </p> </figcaption> </figure> <p id=\"P30\"> To gain potential insights into the extent of immune interactions in SCLC, we quantified the degree of compartmentalization between immune and tumor cells among immune-hot tumors (&gt; 250 immune cells/FoV). We defined an immune-tumor mixing score as the ratio of immune-cancer-cell interactions to immune-stromal-cell interactions (defining stroma as all non-cancer cells), whereby a larger ratio corresponds to greater mixing ( <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ). To benchmark this metric, we leveraged a published triple-negative breast cancer (TNBC) dataset ( <a aria-describedby=\"R49\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R49\"> Keren et al., 2018a </a> ), as no MIBI comparator is available in LUAD. We found that the distribution of the immune-tumor mixing score among immune-hot SCLC tumors (N = 13) was significantly lower than in immune-hot TNBC tumors (N = 34) (Welch\u2019s t-test p = 0.026; <a class=\"usa-link\" href=\"#F5\"> Figures 5A </a> , <a class=\"usa-link\" href=\"#F5\"> 5C </a> and <a class=\"usa-link\" href=\"#SD1\"> S4F </a> ). Collectively, we find evidence of 1) decreased immune infiltrate in SCLC and particularly SCLC-N subtype, and 2) immune sequestration in SCLC cases that do contain more immune cells. </p> </section> <section id=\"S10\"> <h3 class=\"pmc_sec_title\"> SCLC-N exhibits greater T-cell dysfunction </h3> <p id=\"P31\"> We next wanted to assess differences in immune subsets within the SCLC TME at the single-cell level. To this end, we pooled immune cells across the 21 SCLC samples in our cohort (N = 16,475 cells), using immune cells from LUAD (N = 45,535 cells) and normal adjacent lung (N = 10,934 cells) as a reference ( <a class=\"usa-link\" href=\"#SD1\"> Figure S5A </a> ). We analyzed the myeloid and T-cell compartments separately to facilitate cell type annotation ( <a class=\"usa-link\" href=\"#F5\"> Figures 5D </a> , <a class=\"usa-link\" href=\"#SD1\"> S5A </a> \u2013 <a class=\"usa-link\" href=\"#SD1\"> E </a> , <a class=\"usa-link\" href=\"#SD1\"> S6C </a> \u2013 <a class=\"usa-link\" href=\"#SD1\"> F </a> and <a class=\"usa-link\" href=\"#SD1\"> S7C </a> ; <a class=\"usa-link\" href=\"#SD19\"> Table S18 </a> ; <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ). Our cohort is well-balanced with respect to treatment history (7 untreated, 6 treated with chemotherapy and 8 with chemotherapy and immunotherapy) ( <a class=\"usa-link\" href=\"#SD1\"> Figure S1A </a> ). </p> <p id=\"P32\"> To assess how SCLC subtype impacts T-cell phenotype, we applied non-negative matrix factorization (NMF) ( <a aria-describedby=\"R20\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R20\"> Chung et al., 2017 </a> ; <a aria-describedby=\"R74\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R74\"> Puram et al., 2017 </a> ; <a aria-describedby=\"R90\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R90\"> Stein-O\u2019Brien et al., 2018 </a> ), which excels in settings of continuous phenotypes with uncertain cluster boundaries, and identified 30 factors that facilitate cell-type annotation ( <a class=\"usa-link\" href=\"#SD1\"> Figures S6A </a> and <a class=\"usa-link\" href=\"#SD1\"> S6B </a> ; <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ). Of these factors, 7 correspond to T-cell phenotypes: CD4+ regulatory (Tregs, factor 4), CD4+ conventional (Tconv, factors 19 and 23), CD8+ exhausted (Texh, factor 7), CD8+ memory (Tmem, factor 12), CD8+ effector (Teff, factor 28), and CD8+ gamma delta T-cells (Tgd, factor 29) ( <a class=\"usa-link\" href=\"#SD1\"> Figure S6C </a> ; <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ). A parallel cluster-based phenotyping approach confirmed the annotation of discrete T-cell phenotypes ( <a class=\"usa-link\" href=\"#SD1\"> Figures S6D </a> \u2013 <a class=\"usa-link\" href=\"#SD1\"> F </a> ; <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ). To assess whether any T-cell phenotypes are enriched by subtype, we compared factor loadings between SCLC-A and SCLC-N while adjusting for treatment and tissue. SCLC-N exhibits significantly higher Treg factor 4 and CD8+ exhausted factor 7, as well as significantly lower CD8+ effector-like factor 28 and Tgd factor 29 compared with SCLC-A ( <a class=\"usa-link\" href=\"#SD1\"> Figure S6G </a> ). A low ratio of CD8+ effector to Treg cells has been correlated with poor prognosis in cancer patients in a variety of contexts ( <a aria-describedby=\"R7\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R7\"> Baras et al., 2016 </a> ; <a aria-describedby=\"R73\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R73\"> Preston et al., 2013 </a> ; <a aria-describedby=\"R84\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R84\"> Shang et al., 2015 </a> ). The ratio of CD8+ effector to Treg factor loadings is significantly lower in SCLC-N than SCLC-A (p = 0.001; <a class=\"usa-link\" href=\"#F5\"> Figure 5E </a> ; <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ) and is robust to the number of factors ( <a class=\"usa-link\" href=\"#SD1\"> Figure S6H </a> ). This measure of immunosuppression is consistent with a parallel cluster-based CD8+ effector/Treg ratio (p = 0.001; <a class=\"usa-link\" href=\"#SD1\"> Figure S6I </a> ; <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ). </p> <p id=\"P33\"> We sought to validate these findings by imaging the independent SCLC cohort (N = 35 passing quality control). Given the relatively low T-cell representation in SCLC (mean 1.7% of cells \u00b1 s.d. 4.2% across samples, estimated by MIBI-TOF), we chose to use Vectra rather than MIBI imaging to assess T-cell abundance, as Vectra has (1) a substantially larger FoV, (2) greater sensitivity for FOXP3 staining, and (3) access to more treatment-naive tumors that pass quality control. As a proxy for SCLC subtype, we divided samples according to NEUROD1 positivity in IHC due to the near absence of any ASCL1\u2212 samples in this cohort. We found a similarly reduced ratio of CD8+ T-cells to Tregs in NEUROD1+ samples (p = 0.009; <a class=\"usa-link\" href=\"#F5\"> Figures 5F </a> and <a class=\"usa-link\" href=\"#F5\"> 5G </a> ; <a class=\"usa-link\" href=\"#SD15\"> Table S14 </a> ; <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ). Our findings identify compositional differences between SCLC-A and SCLC-N T-cell populations, including relative depletion of cytotoxic T-cells and increase in Tregs in SCLC-N. </p> </section> <section id=\"S11\"> <h3 class=\"pmc_sec_title\"> Populations resembling fibrosis-associated macrophages are enriched in SCLC metastases </h3> <p id=\"P34\"> To examine the myeloid compartment, we reclustered these cells from SCLC samples in our scRNA-seq dataset (N = 2,951 cells), resulting in 7 monocyte/macrophage (Mono/M\u03c6), 4 neutrophil, and 2 dendritic clusters ( <a class=\"usa-link\" href=\"#F6\"> Figure 6A </a> ; <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ; see <a class=\"usa-link\" href=\"#SD1\"> Figures S7A </a> \u2013 <a class=\"usa-link\" href=\"#SD1\"> B </a> for mapping to the combined SCLC, LUAD, and normal lung myeloid dataset). SCLC myeloid clusters 1, 7, 9, and 12 represent a subset of <em> THBS1+ VCAN+ </em> Mono/M\u03c6 cells that overexpress genes related to the extracellular matrix (ECM), including <em> VCAN, FCN1, S100A4, S100A6, S100A8 </em> and <em> S100A9 </em> ( <a class=\"usa-link\" href=\"#F6\"> Figures 6A </a> and <a class=\"usa-link\" href=\"#SD1\"> S7C </a> ; <a class=\"usa-link\" href=\"#SD20\"> Table S19 </a> ; <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ). This phenotype resembles monocytic myeloid-derived suppressor cells (MDSCs) in mice ( <a aria-describedby=\"R33\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R33\"> Gao et al., 2012 </a> ) and MDSC-like M\u03c6 expressing <em> THBS1+ </em> S100 proteins in human hepatocellular carcinoma ( <a aria-describedby=\"R106\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R106\"> Zhang et al., 2019b </a> ). </p> <figure class=\"fig xbox font-sm\" id=\"F6\"> <h4 class=\"obj_head\"> Figure 6: SCLC tumors are associated with a pro-fibrotic, immunosuppressive Mono/M\u03c6 subset. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <img alt=\"Figure 6:\" class=\"graphic\" height=\"2100\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e35b/8628860/e8b680cdfb22/nihms-1754019-f0007.jpg\" width=\"1942\"/> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/F6/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p id=\"P222\"> (A) UMAP of SCLC myeloid cells (N=2,951 cells) annotated by myeloid cell type (left) and clusters within the SCLC compartment only (right). </p> <p id=\"P223\"> (B) Heatmap showing normalized mean expression of select markers from the IPF-associated profibrotic macrophage gene signature( <a aria-describedby=\"R1\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R1\"> Adams et al., 2020 </a> ) (N=143 genes with log fold change &gt; 0.3) per Mono/M\u03c6 subsets. Expression is imputed using MAGIC (k=30, t=3) and scaled from 0 to 1 across clusters. Left barplot shows average z-scored gene expression across the entire gene signature per cluster. Clusters (rows) ordered by signature score. </p> <p id=\"P224\"> (C) UMAP of SCLC myeloid cells showing gene signature scores for IPF-associated pro-fibrotic macrophages (left) and monocytes (right). Scores are calculated by taking the average Z-score of imputed expression of a given gene set, taken from( <a aria-describedby=\"R1\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R1\"> Adams et al., 2020 </a> ). </p> <p id=\"P225\"> (D) Heatmaps showing normalized mean imputed expression of IPF-associated pro-fibrotic macrophage (left) and monocytic (right) gene signatures( <a aria-describedby=\"R1\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R1\"> Adams et al., 2020 </a> ) per SCLC Mono/M\u03c6 cluster, as described in (B). </p> <p id=\"P226\"> (E) Boxplot showing the proportion of pro-fibrotic Mono/M\u03c6 in each sample of the combined LUAD and SCLC myeloid compartment (combined myeloid cluster 6, which includes SCLC clusters 1 and 7) in different histologies for all samples (N=48) and treatment-naive samples (N=23). We also denote in the overlying swarmplot which samples are matched to the same patient (Mann-Whitney test; error bars: 95% confidence interval). p-values: *&lt;0.05, **&lt;0.01, ***&lt;0.001. </p> <p id=\"P227\"> See also <a class=\"usa-link\" href=\"#SD1\"> Figures S6 </a> \u2013 <a class=\"usa-link\" href=\"#SD1\"> S7 </a> and <a class=\"usa-link\" href=\"#SD19\"> Tables S18 </a> \u2013 <a class=\"usa-link\" href=\"#SD20\"> S19 </a> . </p> </figcaption> </figure> <p id=\"P35\"> Given that clusters 1, 7, 9, and 12 belong to a Mono/M\u03c6 subset known to secrete ECM-related proteins, we compared these to myeloid populations in idiopathic pulmonary fibrosis (IPF)( <a aria-describedby=\"R1\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R1\"> Adams et al., 2020 </a> ). This subset, and clusters 1 and 7 in particular, closely resemble previously defined IPF-associated macrophage populations ( <a class=\"usa-link\" href=\"#F6\"> Figure 6B </a> ). Cluster 1 scores highest for a profibrotic macrophage signature within IPF, and cluster 7 scores highest for a monocytic signature within IPF ( <a class=\"usa-link\" href=\"#F6\"> Figures 6C </a> and <a class=\"usa-link\" href=\"#F6\"> 6D </a> ). </p> <p id=\"P36\"> Unsupervised clustering of the combined myeloid compartment of SCLC, LUAD, and normal lung identified a single cluster (\u2018combined cluster 6\u2019), which is comprised of Mono/M\u03c6 from SCLC clusters 1 and 7 (N = 514 cells from 14 SCLC samples) and from LUAD samples (N = 467 cells from 6 LUAD samples), but none from normal lung ( <a class=\"usa-link\" href=\"#SD1\"> Figures S7A </a> \u2013 <a class=\"usa-link\" href=\"#SD1\"> B </a> ). We found that the fraction of combined cluster 6 cells out of all Mono/M\u03c6 cells is significantly higher in primary and metastatic SCLC samples compared to primary LUAD, whereas these cells are undetected in normal lung and metastatic LUAD ( <a class=\"usa-link\" href=\"#F6\"> Figure 6E </a> ). The enrichment in SCLC is even more striking in untreated samples. Combined cluster 6 cells are also enriched, but not significantly, in metastatic compared to primary SCLC. </p> <p id=\"P37\"> We sought to characterize the transcriptional profile of SCLC Mono/M\u03c6 cluster 1 resembling profibrotic IPF-associated macrophages. Differential expression ( <a class=\"usa-link\" href=\"#SD1\"> Figure S7D </a> ; <a class=\"usa-link\" href=\"#SD20\"> Table S19 </a> ) identified cluster 1 as a <em> CD14 </em> + <em> CD16+ (FCGR3A) CD81+ ITGAX </em> + <em> CSF1R </em> + subpopulation that secretes specific pro-fibrotic, pro-metastatic growth factors involved in ECM deposition and remodeling( <a aria-describedby=\"R99\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R99\"> Winkler et al., 2020 </a> ), including fibronectin 1 ( <em> FN1 </em> ) ( <a aria-describedby=\"R68\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R68\"> Park and Helfman, 2019 </a> ; <a aria-describedby=\"R98\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R98\"> Wang and Hielscher, 2017 </a> ), cathepsins ( <em> CTSB </em> and <em> CTSD </em> ) ( <a aria-describedby=\"R27\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R27\"> Egeblad and Werb, 2002 </a> ; <a aria-describedby=\"R40\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R40\"> Guo et al., 2002 </a> ), and osteopontin ( <em> SPP1 </em> ) ( <a aria-describedby=\"R38\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R38\"> Giopanou et al., 2017 </a> ; <a aria-describedby=\"R67\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R67\"> Pang et al., 2019 </a> ). In addition, cluster 1 upregulates genes related to immune inhibition, including (1) <em> SPP1 </em> , implicated in T-cell suppression and tumor immune evasion in colon cancer ( <a aria-describedby=\"R85\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R85\"> Shurin, 2018 </a> ) and NSCLC ( <a aria-describedby=\"R58\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R58\"> Lin et al., 2015 </a> ); (2) <em> CD74 </em> , implicated in both immune suppression in metastatic melanoma ( <a aria-describedby=\"R31\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R31\"> Figueiredo et al., 2018 </a> ) and migration inhibitory factor-induced pulmonary inflammation ( <a aria-describedby=\"R93\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R93\"> Takahashi et al., 2009 </a> ); and (3) <em> VSIG4 </em> , implicated in macrophage suppression ( <a aria-describedby=\"R57\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R57\"> Li et al., 2017 </a> ). Collectively, these findings suggest that cluster 1 is a subpopulation with a pro-fibrotic and immunosuppressive Mono/M\u03c6 phenotype that is selectively increased in SCLC. Further functional analyses would be required to assess whether this population contributes to SCLC tumorigenesis or metastasis. </p> </section> <section id=\"S12\"> <h3 class=\"pmc_sec_title\"> The recurrent PLCG2-high SCLC population is associated with a pro-fibrotic, immunosuppressive Mono/M\u03c6 subpopulation and CD8+ T-cell exhaustion </h3> <p id=\"P38\"> We hypothesized that the subset of pro-fibrotic, immunosuppressive Mono/M\u03c6 cells might interact with specific cancer subpopulations to facilitate progression. We found that SCLC-A is significantly correlated with Mono/M\u03c6 clusters 2 and 12, whereas SCLC-N is significantly correlated with clusters 1 and 9 (p &lt; 0.01 and p &lt; 0.01; <a class=\"usa-link\" href=\"#F7\"> Figure 7A </a> ; <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ). We asked whether these myeloid clusters are correlated with cancer phenotypes associated with SCLC-N and found that clusters 1, 7, and 9\u2014which most closely resemble IPF-associated Mono/M\u03c6 ( <a class=\"usa-link\" href=\"#F6\"> Figure 6C </a> )\u2014are significantly correlated with EMT in SCLC cells (p &lt; 0.001, p &lt; 0.01 and p &lt; 0.001, respectively; <a class=\"usa-link\" href=\"#F7\"> Figure 7A </a> ). Beyond canonical SCLC subtypes, we tested for associations with the recurrent <em> PLCG2 </em> -high SCLC subpopulation and found a significant correlation with Mono/M\u03c6 clusters 1 and 7 (p &lt; 0.01 and p &lt; 0.01, respectively; <a class=\"usa-link\" href=\"#F7\"> Figure 7A </a> ). Separately, we found that Mono/M\u03c6 cluster 1 is enriched in samples harboring the recurrent SCLC cluster and that this enrichment is robust to sampling (p = 0.018; <a class=\"usa-link\" href=\"#SD1\"> Figure S7E </a> and <a class=\"usa-link\" href=\"#SD1\"> S7F </a> ; <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ). We also confirmed that the profibrotic Mono/M\u03c6 population is significantly correlated with <em> PLCG2 </em> and EMT gene signatures in independent bulk RNA-seq datasets (N = 81; <a class=\"usa-link\" href=\"#SD1\"> Figure S7G </a> ) ( <a aria-describedby=\"R37\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R37\"> George et al., 2015 </a> ; <a aria-describedby=\"R77\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R77\"> Rudin et al., 2012 </a> ). </p> <figure class=\"fig xbox font-sm\" id=\"F7\"> <h4 class=\"obj_head\"> Figure 7: The recurrent <em> PLCG2 </em> -high SCLC phenotype is associated with the pro-fibrotic, immunosuppressive Mono/M\u03c6 subset and exhausted CD8+ T-cells. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <img alt=\"Figure 7:\" class=\"graphic\" height=\"2100\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e35b/8628860/59d9e0998156/nihms-1754019-f0008.jpg\" width=\"2073\"/> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/F7/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p id=\"P228\"> Heatmaps showing covariate-adjusted Spearman\u2019s correlation of SCLC phenotypes with (A) Mono/M\u03c6 subsets and (B) coarse immune cell types. Mono/M\u03c6 in (A) are arranged along columns from low to high score for IPF-associated Mono/M\u03c6, as in <a class=\"usa-link\" href=\"#F6\"> Figure 6C </a> . Treatment and tissue covariates were adjusted ( <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ). Tumor features in (A) are arranged by hierarchical clustering using Euclidean distance and average linkage. Tumor features in (B) follow the ordering in (A) for readability. p-values: *&lt;0.05, **&lt;0.01, ***&lt;0.001. </p> <p id=\"P229\"> (C) Color overlay of SCLC tumor MIBI 12 at FoV 1 (500 \u00d7 500 \u03bcm) showing the co-occurrence of the PLCG2-positive SCLC cells and the putative profibrotic Mono/M\u03c6. Left: Channels dsDNA (violet), Vimentin (white), CD8 (yellow), CD31 (orange), CD68 (red), CD163 (red), and FOXP3 (cyan) illustrate the global tumor environment structure. Middle: Channels PLCG2 (red), CD56 (yellow), and NEUROD1 (cyan) identify PLCG2+ tumor. Right: Channels CD14 (orange), CD16 (cyan), and CD81 (magenta) identify the profibrotic Mono/M\u03c6. </p> <p id=\"P230\"> (D) FoV from the (C) now visualized with segmented cancer cells using Mesmer( <a aria-describedby=\"R39\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R39\"> Greenwald et al., 2021 </a> ), represented by dots colored by PLCG2+ SCLC cells vs profibrotic Mono/M\u03c6. </p> <p id=\"P231\"> (E) Barplot of covariate-adjusted Spearman\u2019s correlation between the percent of PLCG2+ SCLC cells and the fraction of different cell types/states in MIBI-TOF of an independent TMA cohort. The following covariates were adjusted: SCLC subtype (NEUROD1+/\u2212), treated vs naive, combined vs single histology and distant metastasis vs primary (Student\u2019s t-test; <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ). PLCG2+ SCLC cells had the highest correlation with CD14+ CD16+ CD81+ Mono/M\u03c6, shown in blue (r=0.75, N=37, Bonferroni-adjusted p = 1 \u00d7 10 <sup> \u22126 </sup> ; <a class=\"usa-link\" href=\"#S14\"> STAR methods </a> ). </p> <p id=\"P232\"> (F) Scatterplot of residuals for the fraction of CD14+ CD16+ CD81+ myeloid cells out of all myeloid cells (representing the profibrotic Mono/M\u03c6) vs the fraction of PLCG2+ SCLC cells out of all SCLC cells (representing the recurrent <em> PLCG2 </em> -high SCLC phenotype). Residuals correspond to the partial correlation described in (E). Example patient MIBI 12 from <a class=\"usa-link\" href=\"#F7\"> Figures 7C </a> is indicated. </p> </figcaption> </figure> <p id=\"P39\"> We also assessed whether SCLC phenotypes are correlated with non-myeloid immune subpopulations. Notably, the <em> PLCG2 </em> -high subpopulation is the only SCLC phenotype that correlates significantly with exhausted CD8+ T cells (p &lt; 0.0001, <a class=\"usa-link\" href=\"#F7\"> Figures 7B </a> ; <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ). We confirmed significant correlation of CD8+ T-cell exhaustion to profibrotic Mono/M\u03c6 and <em> PLCG2 </em> in published bulk RNA-seq datasets (N = 81; <a class=\"usa-link\" href=\"#SD1\"> Figure S7G </a> ). </p> <p id=\"P40\"> Finally, we sought to validate the association of PLCG2-positive SCLC cells with the profibrotic Mono/M\u03c6 population using MIBI-TOF on an independent cohort of SCLC tumors (N = 37). We used the specific combination of CD14, CD16, and CD81 markers to differentiate the putative profibrotic Mono/M\u03c6 cells from other myeloid cells ( <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ) and found that PLCG2-positive SCLC cells coexist with this population in a number of patients. For example, in patient MIBI 12, we find a subset of NEUROD1+ SCLC cells with PLCG2 positivity adjacent to a population of profibrotic Mono/M\u03c6 cells ( <a class=\"usa-link\" href=\"#F7\"> Figures 7C </a> and <a class=\"usa-link\" href=\"#F7\"> 7D </a> ). We see a similar association of NEUROD1+ SCLC cells with PLCG2 positivity and profibrotic Mono/M\u03c6 in patient MIBI 3 ( <a class=\"usa-link\" href=\"#SD1\"> Figures S7H </a> and <a class=\"usa-link\" href=\"#SD1\"> S7I </a> ). Across the MIBI-TOF cohort, we found that the fraction of CD14+ CD16+ CD81+ myeloid cells is better correlated with the fraction of PLCG2+ SCLC cells than all other tumor and immune cell types and states (adjusted partial Spearman\u2019s r = 0.75, Bonferroni-adjusted p = 6.71 \u00d7 10 <sup> \u22128 </sup> ; <a class=\"usa-link\" href=\"#F7\"> Figure 7E </a> \u2013 <a class=\"usa-link\" href=\"#F7\"> F </a> ; <a class=\"usa-link\" href=\"#S14\"> STAR Methods </a> ). Together, our findings suggest that this recurrent SCLC subpopulation may exist in an immunosuppressed TME characterized by exhausted CD8+ T-cells and a pro-fibrotic, immunosuppressive Mono/M\u03c6 population that may be associated with EMT. </p> </section> </section> <section id=\"S13\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"S13-anchor\"> </a> DISCUSSION </h2> <p id=\"P41\"> SCLC was classically considered a homogeneous disease based on its highly consistent histology, but more recent analyses have revealed distinct transcriptomic subtypes ( <a aria-describedby=\"R78\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R78\"> Rudin et al., 2019 </a> ) with potential prognostic and therapeutic implications ( <a aria-describedby=\"R60\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R60\"> Mollaoglu et al., 2017 </a> ; <a aria-describedby=\"R81\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R81\"> Saunders et al., 2015 </a> ). Here, we expose a level of biological complexity that cannot be described by bulk-level subtyping, demonstrating that SCLC tumors\u2014particularly SCLC-N\u2014are more heterogeneous than LUAD and that SCLC has the potential for plasticity and interconversion between subtypes, particularly SCLC-A and -N. </p> <p id=\"P42\"> Despite substantial clinical heterogeneity in patients with SCLC, we detected a subpopulation that was shared among tumors across subtypes, treatments, and tissue locations, pointing to a potentially universal characteristic of this malignancy. This subpopulation demonstrates a pro-metastatic, stem-like phenotype marked by profound <em> PLCG2 </em> overexpression. Signaling by the related phospholipase <em> PLCG1 </em> has been implicated in promoting metastasis in other tumor types ( <a aria-describedby=\"R48\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R48\"> Kassis et al., 1999 </a> ; <a aria-describedby=\"R80\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R80\"> Sala et al., 2008 </a> ). Direct genetic manipulation validated that <em> PLCG2 </em> expression promotes pro-metastatic and stem-like features. We further found that <em> PLCG2 </em> expression is significantly higher in metastases and correlates with worse overall survival. While these results demonstrate the utility of PLCG2 as a single prognostic marker, tracking the recurrent <em> PLCG2 </em> -high subpopulation in our scRNA-seq data demonstrated an even greater hazard ratio than PLCG2 expression alone, suggesting that additional factors determine the full phenotype of the recurrent cluster. Even though the recurrent <em> PLCG2 </em> -high SCLC cluster constitutes a minor fraction of the malignant cells comprising the tumors under study, this small subpopulation has a strong correlation with survival, illustrating its prognostic importance and the value of single-cell analysis. </p> <p id=\"P43\"> Analysis of the TME in our data confirmed an immune-cold phenotype in SCLC, particularly in SCLC-N, notable for more Tregs and fewer CD8+ T-cells than SCLC-A. Analysis of the myeloid milieu revealed that SCLC is enriched for a subset of Mono/M\u03c6 with an immunosuppressive phenotype resembling IPF-associated macrophages. One specific Mono/M\u03c6 cluster displayed a pro-fibrotic, immunosuppressive phenotype. Among the SCLC cohort, we identified a constellation of immune and tumor phenotypes (exhausted CD8+ T-cells and pro-fibrotic Mono/M\u03c6) associated with SCLC-N, EMT, and the recurrent <em> PLCG2 </em> -high phenotype. These associations raise the possibility that CD8+ T-cells in the TME of the <em> PLCG2+ </em> SCLC subpopulation are impeded by immunosuppressive Mono/M\u03c6 cells. This same Mono/M\u03c6 cluster may also provide the fibrotic substrate that facilitates mobility of the pro-metastatic <em> PLCG2 </em> -high subset of cancer cells. Further investigation into these immune populations may reveal novel tumor-immune interactions that enable metastasis. </p> <p id=\"P44\"> Our findings were facilitated by unbiased, high-throughput profiling of SCLC phenotypes and the surrounding immune microenvironment across multiple modalities (scRNA-seq, MIBI, Vectra, FACS and published bulk RNA-seq) and independent cohorts; yet there are important limitations. A portion of our samples come from small biopsies, which may not fully represent the biology of the entire tumor. Additionally, our cohort includes a diversity of treatment histories, tissue locations and SCLC subtypes. Nonetheless, we detected the consistent presence of tumoral and immune subpopulations with potential implications for SCLC metastasis. Further analyses of expanded cohorts with more tightly restricted clinical variables will contribute to further deciphering the role of intratumoral heterogeneity in SCLC. </p> <p id=\"P45\"> The picture of SCLC that emerges from our atlas is that a spectrum of subtypes and a <em> PLCG2 </em> -high recurrent population enlist diverse gene programs to define pronounced heterogeneity and facilitate metastasis in a profoundly immunosuppressed TME. Our dataset has potential implications for the design of novel targeted therapies and immunotherapeutic approaches. </p> </section> <section id=\"S14\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"S14-anchor\"> </a> STAR METHODS </h2> <section id=\"S15\"> <h3 class=\"pmc_sec_title\"> RESOURCE AVAILABILITY </h3> <section id=\"S16\"> <h4 class=\"pmc_sec_title\"> Lead Contact </h4> <p id=\"P46\"> Further information should be directed to and will be addressed by the Lead Contact, Charles Rudin ( <span> rudinc@mskcc.org </span> ). </p> </section> <section id=\"S17\"> <h4 class=\"pmc_sec_title\"> Materials Availability </h4> <p id=\"P47\"> Requests for resources should be directed to and will be addressed by the Lead Contact. </p> </section> <section id=\"S18\"> <h4 class=\"pmc_sec_title\"> Data and Code Availability </h4> <p id=\"P48\"> Software and tools used for the enclosed data analysis will be provided open source at <a class=\"usa-link usa-link--external\" href=\"http://github.com/dpeerlab\" rel=\"noopener noreferrer\" target=\"_blank\"> http://github.com/dpeerlab </a> . In collaboration with the NIH-funded HTAN Data Coordinating Center (U24), single-cell analysis at time of publication will be made available as an interactive, online platform for independent visualization and analysis. MIBI-TOF data will be made available at <a class=\"usa-link usa-link--external\" href=\"https://mskcc.ionpath.com/tracker\" rel=\"noopener noreferrer\" target=\"_blank\"> https://mskcc.ionpath.com/tracker </a> . </p> </section> </section> <section id=\"S19\"> <h3 class=\"pmc_sec_title\"> EXPERIMENTAL MODEL AND SUBJECT DETAILS </h3> <section id=\"S20\"> <h4 class=\"pmc_sec_title\"> Patient cohorts </h4> <p id=\"P49\"> Patients with LUAD or SCLC undergoing a surgical resection or tissue biopsy at Memorial Sloan Kettering Cancer Center (MSKCC) were identified and biospecimens collected prospectively from 2017 to 2019. All patients from whom biospecimens were obtained provided informed consent through an Institutional Review Board-approved biospecimen collection and analysis protocol. Clinical, demographic, pathologic, and molecular data using MSK-IMPACT were identified by retrospective review of the electronic medical record. Single cell RNA-seq were performed on 21 clinical specimens with SCLC, 24 clinical specimens with lung adenocarcinoma, and 4 tumor-adjacent normal lung tissue samples ( <a class=\"usa-link\" href=\"#SD2\"> Table S1 </a> ). IHC for subtyping TFs was performed on the SCLC samples as previously described ( <a aria-describedby=\"R6\" aria-expanded=\"false\" class=\"usa-link\" href=\"#R6\"> Baine et al., 2020 </a> ) and reviewed by a pathologist at MSKCC. </p> <p id=\"P50\"> MIBI and Vectra analyses were performed on a TMA constructed with additional independent SCLC cohorts. IHC was also performed on the same TMA for benchmarking. 26 cases were amenable for IHC evaluation and 12 for Vectra analysis ( <a class=\"usa-link\" href=\"#SD15\"> Table S14 </a> ). For TMA construction, archival formalin-fixed, paraffin-embedded (FFPE) samples were identified and collected retrospectively from SCLC and NSCLC cases between 2007 and 2017. Human kidney samples were used as a positive control in both TMAs. </p> <p id=\"P51\"> Flow cytometry analysis of CD45 positive cells was performed on an independent cohort of 11 SCLC patients ( <a class=\"usa-link\" href=\"#SD18\"> Table S17 </a> ) collected prospectively from 2017 to 2019. </p> </section> <section id=\"S21\"> <h4 class=\"pmc_sec_title\"> Cell lines </h4> <p id=\"P52\"> H82 (male), SHP-77 (male), H526 (male), H446 (male) and DMS-114 (male) were purchased from ATCC, authenticated through the STR characterization method and regularly tested for Mycoplasma. Both cell lines were cultured in RPMI 1640 supplemented with 10% FBS and cultured according to ATCC guidelines. </p> </section> </section> <section id=\"S22\"> <h3 class=\"pmc_sec_title\"> METHOD DETAILS </h3> <section id=\"S23\"> <h4 class=\"pmc_sec_title\"> Sample handling </h4> <p id=\"P53\"> Clinical samples were received in the lab immediately after extraction (Median delivery time\u00b1SEM, 0.75\u00b10.72 hours) and processed rapidly (Median\u00b1SEM processing time from delivery until 10x protocol started, 1.75\u00b10.27 hours) to ensure high sample viability and quality for single cell RNA-seq. </p> <section id=\"S24\"> <h5 class=\"pmc_sec_title\"> Sample processing: Resection and small biopsies dissociation </h5> <p id=\"P54\"> Upon delivery to the lab, samples were mechanically/enzymatically dissociated using the tumor dissociation kit (#130\u2013095-929, Miltenyi) and the GentleMACS ) and a list of known data repositories (bigd.big.ac.cn, massive.ucsd.edu, www.ebi.ac.uk, www.iprox.cn, proteomecentral.proteomexchange.org, www.proteomexchange.org, pdc.cancer.gov, doi.org, www.ncbi.nlm.nih.gov). Please return a JSON array of objects, where each object has the structure:\n- `dataset_id`: The dataset identifier (a code). If not found, set it to 'n/a'.\n- `repository_reference`: The URL or reference to the data repository. If not found, set it to 'n/a'.\nEnsure the output is a plain JSON array, not nested inside another structure."}]